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Abstract
Afflicting almost 200 million worldwide, hepatitis C virus (HCV) mounts a chronic infection of liver
hepatocytes that causes substantial morbidity and mortality. An understanding of host-virus interactions
will drive the development of therapeutics, but research is restrained by available experimental tools. Due
to the cost and unreliability of existing humanized mouse and primate in vivo models, HCV research is
almost exclusively performed using in vitro platforms which suffer from three major limitations. First,
challenges in primary hepatocyte culture and the general non-permissiveness of liver cell lines have
necessitated the use of a uniquely permissive hepatoma line derived from a single donor, questioning the
generalizability of findings to the broader population. Second, this cell line deviates appreciably from
native liver in functions central to HCV infection, including innate immune signaling, polarization, and
proliferation. Third, infection is typically studied using bulk assays with suboptimal specificity,
sensitivity, and content. Here, we describe three technologies for overcoming these limitations in the
study of host-virus interactions. We demonstrate their utility in exploring innate immune signaling, a
clinically significant component of HCV pathogenesis.
Section I describes an in vitro platform for investigating inter-host variations in the natural history of
infection and treatment response. We show that directed differentiation of induced pluripotent stem cells
(iPSCs) yields patient-specific liver tissue that is permissive to HCV and responds to infection with a
robust innate immune response, opening the door to "personalizing" the study and treatment of infection.
In Section II, we demonstrate that tissue-engineered, micropatterned co-cultures (MPCCs) of primary
hepatocytes and supportive stroma are permissive to HCV, enabling investigations in a more natural host.
We then show that innate immune signaling curtails infection in this model, and that its inhibition
enhances infection 2-3 orders of magnitude. Lastly, we use MPCCs to uncover a novel liver
immunoregulatory mechanism whereby innate immune surveillance is depressed, permitting efficient
replication of hepatotropic pathogens.
Finally, Section III details a high-content imaging assay that enables visualization and enumeration of
single viral genomes in individual cells. We demonstrate that single-cell, multiplexed quantification of
viral genomes and host gene transcripts can be used to dissect host-virus interactions, yielding an
unexpected positive correlation between stage of infection and response to an innate immune cytokine.
The solutions described here will enable the pursuit of previously intractable research questions for HCV
and other viruses, accelerating progress towards the development of antivirals and vaccines. Further, the
insights gained regarding the interplay between HCV and innate immunity have important clinical
ramifications, including a novel therapeutic strategy.
Thesis Supervisor: Sangeeta N. Bhatia, MD, PhD
Title: Professor, Health Sciences and Technology/Electrical Engineering and Computer Science
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Figure 1-1. Essential steps of the viral life cycle for hepatitis C virus (HCV). HCV virions enter target
hepatocytes, and from within the endosomal compartments, undergo a complex series of un-packaging
reactions that culminates in release of the viral nucleic acid into the cytosol. This nucleic acid is known
as positive-sense, because it is able to directly recruit a ribosome using an internal ribosomal entry site
(IRES) and direct the production of viral proteins. These proteins are localized on the endoplasmic
reticulum, from where they help replicate the viral genome (through a negative-sense replicative
intermediate that cannot direct protein synthesis); perform essential viral functions such as disruption
of host immune responses; assemble new virions; and ultimately disseminate them from the cell. This
same framework - a life cycle "flow" from entry to release - holds for viruses broadly. ................. 25
Figure 1-2. Thesis overview: addressing questions of host-virus interactions at three size scales. At
the person size scale, we develop a technological solution to understanding differences in infection
between individual people. We then create a model to understand the organ-scale question of how liver
immunity controls hepatotropic infection. Finally, we describe an imaging assay for capturing the
cellular compartmentalization of virus among individual host cells and the host gene expression
interp lay w ith th e virus........................................................................................................................... 36
Figure 2-1. Personalized HCV infection model. Induced pluripotent stem cell-derived hepatocytes from
one donor are infected with HCV from another. ............................................................................... 39
Figure 2-2. Induced pluripotent stem cell (iPSC)-derived hepatocyte-like cells (iHLCs) express
known hepatitis C virus (HCV) host factors. (A) (Left) Phase image of iHLCs. Scale bar = 100 tm.
(Right) Immunofluorescence imaging of iHLCs for albumin (red), HNF-3p (green), and DAPI (blue).
Scale bar = 90 pm. (B) Quantification of liver-specific factors in iHLCs. microRNA-122 expression
blot (for two typical batches of iHLCs, A and B) and quantification by qPCR. Adult human
hepatocytes [187] included as a reference. Albumin (Alb) and alpha 1-antitrypsin (A1AT) secretion by
iHLCs as measured by ELISA. Error bars show s.d. (C) (Left) Immunofluorescence imaging of iHLCs
for HCV entry factors scavenger receptor BI (SRBI) (red) and CD81 (green), with DAPI co-staining
(blue). Scale bar = 40 pm. (Right) Immunofluorescence imaging of iHLCs for HCV entry factors
occludin (OCLN) (red) and claudin 1 (CLDN) (green), with DAPI co-staining (blue). Scale bar = 40
pm. (D) Western blot for HCV entry receptors CD81, SRBI, CLDN, and OCLN, in two typical batches
of iHLCs (A and B) in duplicate samples. (E) Relative expression of HCV host factors [188] by three
batches of iPSCs and iHLCs as determined through gene microarray [82] (A, B, and C). Host factors
organized by gene ontology (GO) biological process terms, including repeats for genes associated with
m u ltip le term s.........................................................................................................................................4 0
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Figure 2-3. iPSC-derived hepatocyte-like cells (iHLCs) as a model for hepatitis C. (A) iHLC cultures
were either infected with HCV reporter virus expressing secreted Gaussia luciferase (GLue) (n=18) or
mock infected (n-6), and subsequently sampled and washed daily. After 7 days (solid gray arrow),
infected iHLCs were treated with NS5B polymerase inhibitor 2'CMA (n=6), NS3/4A protease
inhibitor VX-950 (n=6), or vehicle DMSO (n=6). Drug treatment was discontinued 12 dpi, and
supernatants collected after an additional day of culture were assayed for the presence of infectious
virus by passage onto Huh-7.5s. Medium from Huh-7.5 cells was harvested 5 days post passage for
GLuc assay. (Top) GLuc secretion by iHLCs. RLU = relative light units. DMSO- vs. 2'CMA-treated
cultures was statistically significant: *p < .05, ***p < .001 (one way ANOVA with Tukey post test).
(Bottom) GLuc secretion by Huh-7.5s after passage of iHLC supernatants. DMSO vs. mock was
statistically significant: ***p < .001 (one way ANOVA with Tukey post test). NS5A staining of
infected Huh-7.5s post passage. Scale bar = 50 pm. (B) iHLCs were lysed 14 dpi. Copies of HCV
RNA in lysates were quantified by qRT-PCR. DMSO vs. 2'CMA was statistically significant: ***p <
.001 (one way ANOVA after log transformation with Tukey post test). (C) NS3/4A activity imaging of
HCV-infected iHLCs [191]. Cells in image delimited by lines (white = uninfected, red = infected).
Scale bar = 25 pm. Data in A-C are means, error bars show s.d........................................................ 42
Figure 2-4. iPSC-derived hepatocyte-like cells (iHLCs) demonstrate an inflammatory response to
hepatitis C virus infection. (A) mRNA expression of innate immune/inflammatory markers in lysates
of infected, DMSO-treated iHLCs relative to mock at 2 and 14 dpi as determined by qPCR. (B) TNF-a
secretion by HCV- and mock-infected iHLCs 14dpi as determined by ELISA. Difference was
statistically significant: *p < .05. Data in A and B are means, error bars show s.d........................... 43
Figure 3-1. Micropatterned co-cultures (MPCCs) of human primary adult hepatocytes and
supportive stroma. Progressively magnified phase images of hepatocytes in micro-patterned co-
cultures (islands 500 pm in diam eter) ................................................................................................ 50
Figure 3-2. Primary human hepatocytes in MPCCs form polarized cell layers, express HCV entry
factors, and support HCV glycoprotein-mediated entry. Bright field images of primary hepatocytes
in MPCCs (a) and in mono-cultures (b). Wide-field fluorescence images of fixed MPCCs stained for
the canalicular marker multidrug resistance-associated protein 2 (MPR2) (c), and the basolateral
marker CD26 (d). Nuclear (blue) and antigen-specific staining (green) for CD81 (e), scavenger
receptor class B member 1 (SCARB1) (f), claudin 1 (CLDN1) (red) (g), and occludin (OCLN) (h) in
MPCCs. (i) Merged image of primary hepatocytes stained for MRP2 (green), zona occludens protein 1
(ZO1) (red), and nuclei (blue). (j) 3D rendering of boxed area in (i). (k) Infection of MPCCs with
retroviral pseudoparticles bearing HCV glycoproteins (HCVpp), vesicular stomatitis virus glycoprotein
(VSVGpp), or no glycoproteins (Env-pp), and containing an enhanced green fluorescent protein
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(EGFP) reporter gene. Representative images are shown for all experiments. (1) Anti-CD81 antibody
blocks entry of HCVpp (dark bars), but not VSVGpp (white bars). Concentrations of antibody (pig/mL)
are noted. Mean and s.d. are shown. Scale bars: 100 pm (a, b, k), 50 pm (c, d), 20 ptm (e-i). .......... 50
Figure 3-3. HCV entry factor staining in normal human liver. Wide-field fluorescence images of
fixed sections of human liver from normal uninfected donors stained nuclei (blue in merged image)
and antigen-specific staining (green in merged image) for CD81 (Upper), SCARB1 (Middle) and
C LD N 1 (L ow er). Scale bars: 30 im ................................................................................................... 51
Figure 3-4. Primary hepatocytes in MPCCs maintain HCVcc infection over longer periods of time
than conventional hepatocyte systems. Conventional, pure hepatocyte cultures, widely used in the
pharmaceutical industry, and MPCCs were created from the same donors. Conventional cultures were
infected with HCVcc within 24 h of plating, whereas MPCCs were infected once they achieved
functional stability (6 days after plating). Luciferase activity in supernatants was monitored over 2
weeks post-infection. One representative time point (6-12 days post-infection) is shown. Luciferase
activity is expressed as percent of m ock control. ............................................................................... 53
Figure 3-5. Primary human hepatocyte MPCCs are susceptible to HCV. (A) Persistent infection of
primary human hepatocytes with HCVcc. Primary hepatocytes in MPCC were infected with
Jc1FLAG2(p7-nsGluc2A). After 24 h, virus was removed and MPCC medium containing DMSO
(0.1%) or the indicated inhibitors was added. All inhibitors were used at approximately 50x IC50
(polymerase inhibitor 2'CMA = 2.16 mM, protease inhibitor ITMN191 = 0.16 mM, IFN-a = 500
U/mL). Samples were taken daily and the media replaced with washing every 48 h. Accumulated
luciferase activity in the supernatants is plotted. Arrows indicate the addition of fresh inhibitor. (B)
Visualization of HCV infection in primary human hepatocytes. MPCCs were transduced with
lentiviruses expressing wild-type (wt) or mutant (C508Y) RFP-NLS IPS HCV reporter. 24 h after
transduction, MPCCs were infected with Jc1FLAG2(p7-nsGluc2A) or plasma from HCV-infected
patients in the presence of heparin (5 IU), CaCl2 (9 mM), and MgCl2 (6 mM). 12 h post-infection,
virus was removed and MPCC medium was added. Un-fixed MPCCs were imaged by wide-field
fluorescence microscopy at 48 h postinfection. Representative pseudo-colored fluorescent images are
shown; white arrow heads show nuclear RFP, indicative of HCV infection. Scale bar: 20 im. ........... 54
Figure 3-6. Miniaturized 96-well primary hepatocyte MPCCs. (A) MPCCs were created in off-the-
shelf tissue culture polystyrene plates in formats up to 96-well plates using soft lithographic
techniques. (B) Each well of a 96-well plate contains 14-15 islands of hepatocytes that are 500 pm in
diameter and spaced 1200 pim apart (center-to-center), and (C) surrounded by 3T3-J2 murine
embryonic fibroblasts to create MPCCs. Scale bars: 2 cm (a), 4 mm (b), 100 pm (c)....................... 55
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Figure 3-7. Primary human hepatocytes in MPCCs produce infectious virus. (a) HCVcc infection
kinetics in primary hepatocyte MPCCs. Primary hepatocytes in MPCCs were infected with
Jc1FLAG2(p7-nsGluc2A) (circles) or mock infected (triangles). After 24 h, virus was removed and
MPCC medium added; samples were taken daily and media replaced with washing three times every
48 h. (b) Schematic of the experimental setup. Supernatants collected pre- and post-wash at days 4, 6,
8, 10, and 12 following infection were used to infect naive Huh-7.5 cells. 24 h post-infection, media
were replaced and nonstructural protein 5A (NS5A) staining was performed 72 h post-infection to
visualize HCV infection. (c) HCV infection of Huh-7.5 cells was visualized by immunocytochemical
staining for NS5A. Days indicate the time points when supernatants were taken from the infected
M P C C cu ltu res. ...................................................................................................................................... 57
Figure 3-8. Utility of primary human hepatocyte MPCCs in antibody and small molecule screening.
(A) Dose-dependent inhibition of HCVcc replication in MPCCs treated with antibodies against HCV
glycoproteins (AP33, 3/11, CBH5, AR3A) or cellular CD81 (JS-8 1). Antibody concentrations are 0.1
(light gray), 1 (dark gray), and 10 (black) tg/mL (B) Dose-dependent inhibition of HCVcc replication
in MPCCs treated with IFN-a (up to 0.13 pM) or small molecules (NS3-4A protease inhibitors,
BILN2061 and ITMN191, or polymerase inhibitor, 2'CMA). HCVcc-infected MPCCs were pulse-
treated for 2 days with compounds and supernatants were collected at days 2 and 4 (shown) post
inhibitor treatment. (C) Drug-drug interactions lead to reduced efficacy of small molecules in HCVcc-
infected MPCCs. Infected MPCCs were treated for 3 days with prototypical inducers of drug
metabolism enzymes [150, 211], followed by treatment of cultures with small molecules for 2 days. In
all experiments, HCVcc replication was monitored by luciferase secretion into the supernatants. Mean
and standard error of the m ean are shown......................................................................................... 59
Figure 3-9. Inhibition of interferon (IFN)-signaling rescues hepatitis C virus (HCV) infection. (A)
JAK inhibitor (JAKi) was dosed (1 pM) starting one day pre-infection and continuously thereafter.
Parainfluenza virus 5 V protein (PIV5 V) was lentivirally introduced 3 days pre-infection to give time
for expression. BX-795 inhibitor of TBK1 and IKKs was dosed (1 gM) starting one day pre-infection
and continuously thereafter. Relative light units (RLU) from Gluc-expressing HCV presented on a
logarithmic scale versus days post infection (DPI). Difference between any intervention and control
(CTL) was highly significant at all time-points by ANOVA. (B) NS3/4A reporter [57] translocations
per MPCC island shown 7 dpi (approximately 200 heps/island) (n > 75 per condition). Difference
between any intervention and CTL significant by ANOVA. (C) Viral titer (TCID50/mL) presented on
a log scale for 7 dpi as determined by passaging onto naive Huh-7.5s. Difference between any
intervention and CTL significant by ANOVA. Data in (A)-(C) are presented as p a. ....................... 63
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Figure 3-10. Linear range of dose response of JAK inhibitor (JAKi) and BX-795. Compounds were
dosed starting one day pre-infection and continuously dosed thereafter. Luminescence produced by
Gluc-expressing HCV shown 9 days post-infection for various doses of compound. Linear regression
performed on these data sets yielded R 2 = .99 for JAKi and R 2 = .97 for BX-795. Data are plotted as [I
............................................................................................................................................................6 4
Figure 3-11. Viral spread in interferon-inhibited MPCCs. NS3/4A reporter imaging [57] in infected,
JAKi-treated MPCCs reveals large "foci" of proximal infected cells. Representative image taken 9 dpi,
focus circled in red dashed line. Scale bar = 100 pm . ...................................................................... 64
Figure 3-12. Interferon-inhibition-mediated enhancement of infection responds to interferon (IFN)
in a mechanistically appropriate manner. Post infection, cultures treated with JAKi, PIV5 V, and
BX-795 as described were treated with IFN-p at several doses or the polymerase inhibitor 2'CMA
(2.16 pM) for 4 days before luminescence was measured by Gluc-expressing HCV. Relative light units
(RLU) presented on a logarithmic scale as p a. ............................................................................. 65
Figure 3-13. Determining specificity of JAKi by testing alternative pathways downstream of JAK
signaling. (A) Numbered list of compounds (targets listed in parentheses) for various signaling
pathways downstream of JAK signaling. (B) Numbered compounds were dosed starting one day pre-
infection and continuously thereafter at 3 doses as listed (compound 4 was tested at lower doses as
listed). Luminescence of Gluc-expressing HCV normalized by untreated infected control and presented
on a log scale as p ± a. Only JAKi elevates infection statistically significantly...............................67
Figure 3-14. Inhibition of interferon-stimulated gene (ISG) induction post hepatitis C virus (HCV)
infection upon inhibition of interferon signaling. Infected cultures were lysed 48 hpi, and RT-PCR
was performed and normalized by a house-keeper. Expression of prototypical ISGs relative to infected
controls is presented for interferon-inhibiting agent treated cultures (dosed as described) as well as
m ock uninfected cultures........................................................................................................................ 67
Figure 3-15. Effect of liver compounds on HCV infection. MPCCs were untreated (CTL) or dosed with
compounds starting one day pre-infection (with Gluc-expressing HCV) and continuously thereafter.
RLU fold over CTL is presented 7 dpi as pzba. Compounds that are significantly above CTL are
presented in green (p < 0.05 as determined by one-way ANOVA followed by Tukey post-test)..........69
Figure 3-16. Inhibition of induction of interferon-stimulated genes (ISGs) post hepatitis C virus
(HCV) infection upon exposure to interleukin (IL)-6. MPCCs were treated with IL-6 (10 ng/mL) or
untreated (CTL) starting 2 days pre-HCV infection and continuously thereafter. Cultures were lysed 3
days post infection and RT-PCR for ISGs (with normalization by a house-keeper) was performed. p +
S E M is sh ow n ......................................................................................................................................... 7 0
16
Figure 3-17. Expression of key elements of the IFN cascade after exposure to IL-6. RT-PCR was
performed for various groups of the IFN pathway cascade, which demonstrated broadly reduced levels
of expression. House-keeper normalized expression for untreated (CTL) and IL-6 (10 ng/mL)
presented as expression fold over CTL, p 0.........................................................................................71
Figure 3-18. IL-6 mediated enhancement of infection is dependent on signal transducer and
activator 3 (STAT3) activity. Cultures were dosed with untreated (CTL) or treated by IL-6 (10
ng/mL) starting 2 days pre-infection (by Glue-expressing HCV), and by carrier control DMSO or by
STAT3 inhibitor WP1066 (10 pM) starting 1 day pre-infection and continuously thereafter. Data
presented as IL-6 RLU fold over untreated CTL, t ± SEM. Two-sided t test confirmed significance (*
p < 0 .0 5 )..................................................................................................................................................7 1
Figure 3-19. Infection by Con1 HCV in MPCCs is increased by innate immune inhibition. (A) Glue-
expressing Con1 RNA was transfected using lipidoids into CTL (DMSO) cultures, PIV5 V transduced
cultures, and IL-6 (10 ng/mL) treated cultures. PIV5 V and IL-6 demonstrated significantly higher
infection (p < 0.05 by one way ANOVA followed by Tukey post-test). Data presented as p a. (B)
NS3/4A infection frequency reporter [192] demonstrated sparse positive events only in
im m unosuppressed cultures....................................................................................................................73
Figure 3-20. Liver-stage malaria infection in MPCCs is increased by innate immune inhibition. (A)
Exoerythrocytic forms (EEFs) of P. falciparum were quantified in CTL (DMSO) treated cultures and
JAKi treated cultures. Difference was statistically significant as verified by t test. (B) EEFs of P.
falciparum were larger in the presence of JAKi treatment. (C) RT-PCR was used to measure IFN and
ISG levels post-infection (by P. berghei) in the presence of CTL, JAKi, or IL-6 treated cultures.
House-keeper-normalized expression is presented relative to CTL expression as p± . .................... 74
Figure 3-21. Model. Microbial antigens from the gut induce Kupffer cells to produce immunoregulators
including interleukin-6 (IL-6) which tolerizes hepatocytes immunologically to inflammatory
substances. This dampened surveillance is in turn exploited by pathogens such as hepatitis C virus
(HCV), which can mount robust infection as a result........................................................................ 76
Figure 4-1. Specific and sensitive imaging of individual molecules of genomic viral RNA (vRNA).
(A) Schematic illustration of single-molecule RNA FISH (smFISH) method [168]. A set of 48 DNA
FISH probes (20 nucleotides/probe) that are each end-labeled with one fluorophore targeting non-
overlapping portions of the target RNA (Left) are introduced to fixed and permeabilized target cells.
Hybridization of probes to the target RNA (Center) produces sufficient local fluorescence for the RNA
molecule to be visualized as a diffraction-limited spot using standard epifluorescence microscopy
(Right). As shown previously, spots are detected only once a minimum number of probes bind the
target, reducing false positives due to random, off-target probe binding. Z-stacks can be performed to
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acquire all such spots in target cells. Using custom software, spots can be identified in three
dimensions and quantified over a wide dynamic range, ranging two orders of magnitude from zero to
several hundred spots per cell; alternatively, for cells with too many spots to identify individually, an
estimate can be obtained by integrating the fluorescence intensity in the cell. Comparison with real-
time polymerase chain reaction (RT-PCR) corroborates transcript enumeration by smFISH spot
counting, showing that smFISH is quantitative. (B) Co-localization of diffraction-limited spots in
infected Huh-7.5 hepatoma cultures (16 hours post infection) was determined by simultaneously
introducing two spectrally distinct probe sets (coupled to Cy5 and Alexa594 respectively) targeting
different portions of the same genomic vRNA strand. Typical images of positive (Left, Z-stack
projection, scale bar ~ 5.0 pm; Inset, ~2x zoom) and negative (Center, Z-stack projection, scale bar ~
4.0 pm; Inset, ~2x zoom) strands shown. Percentage of Cy5 and Alexa594 spots that co-localize with
the other channel shown for both strands (Right). (C) Histogram representation of integrated intensity
distribution for spots 24 hours post infection (hpi) for both strands. (D) Number of positive strands in
individual cells at 12 and 24 hpi (means in red). Difference was statistically significant: ****p <
0.0001 (two-tailed t test). (E) Number of positive strands in individual cells in DMSO or the HCV
NS5B polymerase inhibitor 2'CMA at 24 hpi (means in red). Difference was statistically significant:
****p < 0.0001 (two-tailed t test). (F) NS3/4A activity reporter [57] deems cells infected based on
nuclear fluorescence and uninfected based on cytosolic fluorescence. The Huh-7.5 Clone 8 line which
carries this reporter stably was used to compare NS3/4A imaging with smFISH. Sample images from
the same field of view for both NS3/4A reporter (Left, scale bar ~ 18.5 ptm) and smFISH (Center,
18.5 pm) are shown. Number of positive strands in NS3/4A- or NS3/4A+ cells 24 hpi are provided
(Right). Stat. significant diff: ****p < 0.0001 (two-tailed t test)..................................................... 82
Figure 4-2. Specific and sensitive imaging of viral RNA in hepatoma and primary hepatocyte
culture models. (A) Uninfected Huh-7.5 hepatoma cells imaged with probe sets for both the positive
and negative strand (Z-stack projection, scale bar ~ 4.9 pm). (B) Infected Huh7.5 cells imaged 24
hours post infection (hpi) on DAPI, Cy5, and Alexa594 channels but without FISH probe sets (Z-stack
projection, scale bar ~ 6.2 pim). (C) Structured illumination microscopy (SIM) of HCV (Cy5) and ER
(Alexa594) (scale bar ~ 3.0 pim) in infected Huh-7.5 cells 24 hpi. (D) SIM of HCV (Cy5) and HCV
NS5A (Alexa594) (scale bar ~ 3.7 pm) in infected Huh-7.5 cells 48 hpi. (E) Primary induced
pluripotent stem-cell (iPSC)-derived hepatocyte-like cells imaged 1 week post infection [181] using
confocal microscopy (scale bar ~ 4.7 gm). Alexa594 (green) imaging performed without probe sets as
a control to aid in the identification of frequent lipid-like autofluorescent foci (green arrows) distinct
from diffraction-limited spots specific to the delivered probe set. (F) Primary human fetal liver cells
(HFLCs) imaged 48 hpi by the J6/JFH Clone 2 strain of HCV (Z-stack projection, scale bar ~ 4.2 pm).
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Alexa594 (green) imaging performed without probe sets also to identify occasional autofluorescent
foci (none in this field of view). (G) Number of positive strands in individual HFLCs in DMSO or the
HCV NS5B polymerase inhibitor 2'CMA at 48 hpi (means in red). Difference was statistically
significant: ****p < 0.0001 (two-tailed t test). (H) Fraction of HFLCs "infected" at 48 hpi depending
on the minimum threshold number of genomes for a cell to be deemed infected. NS3/4A activity
reporter [57] infection rate estimate on replicate samples provided as a comparison........................84
Figure 4-3. Single-molecule RNA FISH (smFISH) is a quantitative assay as verified by a novel bulk
assay for quantifying genomic viral RNA (vRNA). (A) Schematic of quantitative polymerase chain
reaction (qPCR) assay for measuring vRNA strands. Briefly, HCV is polyadenylated before
undergoing an RT reaction with a tagged NV-oligo-dT primer. The resulting cDNA is used for qPCR
using the exogenous tag primer and a strand-specific HCV primer directed towards the RNA 3' end.
(B) Sensitivity of method as shown by cycle threshold (Ct) as a function of strand copies. (C)
Specificity of method as shown by positive/negative strand ratio range within which single,
unambiguous PCR products were identified. (D) qPCR comparison with smFISH-based quantification
of HCV positive strands. Number of positive strands in individual cells shown at 12 hpi and 24 hpi
(means in green), with fold increase visualized by green arrow (Left). Fold increase measured by both
assays (Right). Data plotted as mean (p) ± standard error of the mean (SEM). Difference was not
statistically significant (n.s.) (p > 0.05) by two-tailed t test. (E) Assay comparison for negative strands.
Number of negative strands in individual cells shown at 12 hpi and 24 hpi (means in red), with fold
increase visualized by red arrow (Left). Fold increase measured by both assays (Right). Data plotted as
± SEM. Difference was not statistically significant (n.s.) (p > 0.05) by two-tailed t test. .............. 89
Figure 4-4. Multiplexed quantification of positive and negative viral strands in individual cells for
illuminating viral replication. (A) Schematic illustration of experiment. Huh-7.5 hepatoma cells were
inoculated with HCV for 4 hours, and then fixed for smFISH at various times thereafter (Left).
Multiplexed imaging was performed by simultaneously employing an Alexa594 probe set for the
positive strand and a Cy5 probe set for the negative strand (Right). (B) Sample images at 4 (Left, Z-
stack projection, scale bar ~ 7.0 pm) and 48 hpi (Right, Z-stack projection, scale bar ~ 6.0 pm). (C)
Population-wide perspective across whole infection time-course obtained by averaging the number of
observed positive and negative strands for each cell at each time-point (4 hpi: n = 70; 12 hpi: n = 44;
24 hpi: n = 67; 48 hpi: n = 63). Data plotted as mean (p) ± standard deviation (a). The average single-
cell negative-positive strand ratio (NPSR) at each time-point plotted as pt ± a (Inset). (D) Single-cell
joint distribution of positive and negative strands for 48 hpi presented as a scatter plot showing the
strand counts in individual cells (n = 63) (Pearson correlation coefficient p = 0.86). The dashed line
separates the regions in which positive strands are more numerous than negative strands (below, green
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fill) and vice versa (above, red fill). Binning cells by positive strands and obtaining the average single-
cell NPSR for each bin is plotted as t ± c (Inset).............................................................................. 91
Figure 4-5. Bimodal distribution of infection. Positive strand marginal distribution shown as a
frequency histogram at 48 hpi. Bimodality of such distributions is typically observed, with (i) a poorly
infected m ode and a (ii) highly infected m ode. ................................................................................. 93
Figure 4-6. Multiplexed quantification of viral positive strands and host mRNA transcripts in
individual cells for dissecting host-virus interactions. (A) Schematic of concept. A relationship
between infection and host gene expression at the single-cell level (Top) can be identified using
multiplexed smFISH to yield a single-cell joint distribution for these two parameters (Bottom Left);
statistics can be performed to evaluate the association between these parameters, leading to a
conclusion that can assist in addressing hypotheses about host-virus interactions (Bottom Right). (B)
Schematic describing experiment to ascertain relationship between hepatitis C virus (HCV) infection
and interferon-stimulated gene (ISG) expression by dosing with the Type I interferon (IFN), IFN-p.
Infected (48 hpi) or uninfected cells are dosed with 10 U/mL IFN-p for 12 hours before performing
multiplexed smFISH for HCV positive strands and either EIF2AK2 or ISG15. (C) Typical multiplexed
images showing the same field of view 12 hours post dosing of IFN-p in terms of HCV positive strand
(Top, scale bar ~ 17.0 pm) and ISG15 mRNA (Bottom, scale bar ~ 17.0 pm). (D) Joint distributions for
EIF2AK2/HCV (Left) and ISG]5/HCV (Right) visualized as scatter plots. In each plot, the results of
the uninfected experiment are presented on the left (HCV-) where each point represents the number of
ISG mRNA transcripts of individual cells, and on the right are the results of the pre-infected
experiment (HCV+) where each point represents both the number of HCV positive strands and the
number of ISG mRNA transcripts; progressively more infected cells are rightwards on each plot (green
gradient). Gray points are results pre-IFN treatment (dashed mean and best-fit lines), and red points are
results post-IFN treatment (solid mean and best-fit line). For uninfected cells, increase post-IFN was
statistically significant for EIF2AK2 (****p < 0.0001) and for ISG15 (****p < 0.0001) using two-
tailed t test. For infected cells before IFN treatment, there was no positive correlation between ISG
mRNA expression and HCV positive strands for both EIF2AK2 (p > 0.05) and ISG15 (p > 0.05) as
determined by F test on linear regression parameters. For infected cells after IFN treatment, there was a
strong positive correlation between ISG mRNA expression and HCV positive strands for both
EIF2AK2 (****p < 0.0001) and ISG15 (****p < 0.0001) as determined by F test on linear regression
p aram eters............................................................................................................................................... 9 6
Figure 4-7. Association between viral infection and interferon-stimulated gene (ISG) expression. (A)
Typical smFISH images of EIF2AK2 (Left, Z-stack projection, scale bar ~ 9.5 gm) and ISG15 (Right,
Z-stack projection, scale bar ~ 9.5 pm) post IFN-p-treatment (100 U/mL, 48 hours). (B) Number of
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ISG mRNA transcripts in individual cells pre-IFN (gray) or at various times post-IFN-p treatment (10
U/mL) (red) for EIF2AK2 (Left) and ISG15 (Right). Means are shown as dashed or solid lines for pre-
and post-IFN treatment, respectively. Difference between pre-IFN and 6 hours post-IFN are
statistically significant for both EIF2AK2 (****p < 0.0001) and ISG15 (****p < 0.0001). All
differences between post-treatment IFN time-points are non-significant (n.s.) for both EIF2AK2 and
ISG15 (p > 0.05) as determined by one-way ANOVA with Tukey's post-test. (C) Number of HCV
positive strands in individual cells pre-IFN-p and post-IFN-p (10 U/mL) for 12 h (means in black).
Difference was n.s. by two-tailed t test (p > 0.05). (D) Single-cell distribution of number of positive
strands visualized as frequency histogram reveals bimodality with (i) poorly infected and (ii) highly
infected modes. (E) Number of ISG transcripts in individual cells for both EIF2AK2 (Left) and ISG15
(Right) (means in black). On each plot, the number of transcripts in uninfected cells is shown (HCV-),
and on the right (HCV+), the number of transcripts is presented for each cell after splitting cells into a
poorly and highly infected bin based on the number of positive strands (using 200 strands as a
threshold). The difference in ISG expression between uninfected cells and poorly infected cells is n.s.
for both EIF2AK2 and ISG15 (p > 0.05) as determined by two-tailed t test. The difference in ISG
expression between poorly and highly infected cells is highly significant for both EIF2AK2 (****p <
0.0001) and ISG15 (****p < 0.0001) by two-tailed t test. ............................................................... 99
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Chapter 1. Introduction
1.1. Motivation: advancing the study of viral infection
Viruses are obligate intracellular parasites that infect most known forms of life, and human
viruses such as the hepatitis viruses, influenza virus, and human immunodeficiency virus mount
a significant disease burden worldwide. The development of antivirals and vaccines hinges on
our understanding of viruses. Since the onset of modem virology in the 19th century, researchers
have made strides in understanding the origin and evolution of viruses, the viral life cycle, viral
pathogenesis, and host-virus interactions. As in scientific research broadly, many of these
discoveries have been the direct result of advances in tools to assist with experimental
investigation. The use of Chamberland filters in the late 1800s revealed that viral infectious
disease was comprised of material smaller than bacteria. Advances in cell culture and
epidemiology in the early 1900s revealed that variants of the same virus isolated from different
geographic locations had phenotypic differences that could change, suggesting that viruses had
mutable genetic material like other forms of life. Developments in x-ray crystallography enabled
the first visualization of virions in the mid-1900s. And the relatively recent emergence of
recombinant DNA technology in the 1900s opened the door to reverse genetics for dissecting
viral gene function. In this thesis, we consider the study of a clinically relevant liver virus,
hepatitis C virus (HCV). Despite research progress, much about HCV host-virus interactions
remains experimentally intractable due to the limitations of existing research tools. The overall
goal of this thesis was to leverage advances in cell sourcing, tissue engineering, and high-content
imaging to develop technology platforms for overcoming these limitations.
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1.2. A clinically relevant pathogen: hepatitis C virus
1.2.1. Hepatitis C virus as a major clinical problem
Hepatitis C virus (HCV) is transmitted parenterally [1-3]; after the molecular identification of
HCV and development of diagnostics [4, 5], unsafe therapeutic injections was largely supplanted
by intravenous drug use as the primary mode of transmission in developing nations [1, 2]. With a
notable tendency towards establishing a chronic liver infection in as many as 80% of infected
patients [1, 3, 6, 7], HCV has reached epidemic proportions, chronically infecting 170-200
million individuals worldwide [1, 3, 8]. HCV is five times as prevalent as human
immunodeficiency virus 1 (HIV-1), and indeed the most common chronic blood-borne infection
in the United States [1, 9]. Acute infection is typically asymptomatic and thus not diagnosed [1,
3, 10], but persistent infection and consequent liver inflammation leads to hepatic fibrosis over
decades post infection [1, 3, 6, 7] ; as such, HCV is the major cause of chronic liver hepatitis,
cirrhosis, and hepatocellular carcinoma (HCC) worldwide [10, 11], the major cause of death
from liver disease [3], and the leading indication for liver transplantation [1, 3, 10, 12, 13].
Despite ongoing effort, there is no HCV vaccine available [14], and the standard-of-care
therapeutic cocktail of pegylated interferon (IFN)-a and ribavirin is ineffective in 50% of
patients [15]. As such, HCV places a significant burden on the global healthcare system [16].
Drug development research [17] has recently culminated in the development of the exciting new
protease inhibitors telaprevir and boceprevir that can enhance the cure rate of interferon therapy
to 75-90% of patients [18, 19]; despite this impressive advance, however, research towards the
development of prophylactics and therapeutics must continue unabated [20] given that we still
cannot treat 10-25% of patients, the side effects and costs of these therapies, and the looming
fear of resistance emergence.
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1.2.2. Molecular nature and life cycle
Viruses consists of populations of viral particles or virions [21]. These virions contain the viral
genetic nucleic acids that describe how to build new virions and perform viral processes. As
obligate parasites, they depend on hosts to execute their life cycle, which consists of virion entry
into cells, replication of the genetic material within cells, assembly of new virions, and
dissemination from the infected cells for transmission (Figure 1-1). Despite debate regarding the
classification of viruses as living organisms, viruses are subject to the same Darwinian forces of
evolution which tend to maximize ability of viruses to replicate and successfully transmit
themselves. As such, viruses have evolved very different structures and functional strategies in
order to enhance their transmission, and information about viruses should always be interpreted
in this context.
A member of Flaviviridae hepacivirus genus [22], HCV is classified in the same family as
yellow fever virus and dengue virus. HCV is an enveloped, single-stranded RNA virus - HCV
virions consist of a single strand of RNA packaged within a protein capsid that is in turn
enclosed within a glycoprotein-studded lipid bilayer envelope. The single strand of RNA, which
is the HCV genome, is approximately 10 kilobases (kb) long, and has 5' and 3' untranslated
regions (UTRs) [11, 23]. The 5' UTR includes an internal ribosomal entry site (IRES) that is able
to recruit ribosomes in infected hepatocytes without a 5' cap [24]; because the 5' and 3' UTRs
flank a single open reading frame, ribosomal recruitment leads to the production of one large
polyprotein on the endoplasmic reticulum membrane. This polyprotein is subsequently cleaved
by host and viral proteases to generate the 10 viral proteins that enact the HCV viral life cycle.
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The proteins are divided into two categories - the structural proteins (core, El, and E2) and the
non-structural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B). While the structural
proteins comprise the virion capsid and membrane glycoproteins, the non-structural proteins
have various functions such as replication, antagonism of immunity, and assembly of new
virions for infecting other hepatocytes as well as maintaining an infectious blood reservoir for
transmission to other humans.
Figure 1-1. Essential steps of the viral life cycle for hepatitis C virus (HCV). HCV
virions enter target hepatocytes, and from within the endosomal compartments, undergo a
complex series of un-packaging reactions that culminates in release of the viral nucleic
acid into the cytosol. This nucleic acid is known as positive-sense, because it is able to
directly recruit a ribosome using an internal ribosomal entry site (IRES) and direct the
production of viral proteins. These proteins are localized on the endoplasmic reticulum,
from where they help replicate the viral genome (through a negative-sense replicative
intermediate that cannot direct protein synthesis); perform essential viral functions such
as disruption of host immune responses; assemble new virions; and ultimately
disseminate them from the cell. This same framework - a life cycle "flow" from entry to
release - holds for viruses broadly.
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1.3. How we study hepatitis C virus: model systems and assays
Model systems and assays are two central tools in the study of biology and the focus of this
thesis. In this section, we discuss these tools and their use for investigating hepatitis C virus.
1.3.1. Model selection and development
In vitro (cell culture) and in vivo (animal) model systems are central to the advancement of basic
biology and therapy development. No model is perfect, but at the cost of sacrificing
completeness, models enable researchers to experimentally manipulate and interrogate biology.
Model systems can be evaluated in terms of numerous parameters, including the extent of normal
physiology or pathophysiology they are presumed to capture; their amenability to certain types
of experimentation; their accessibility to investigators; and their technical complexity and
associated costs. Models have pros and cons in terms of such parameters, and it is important to
choose a model appropriate for the research goal, which could vary from answering a specific
biological question to high-throughput screening of compounds for therapeutic efficacy. Model
selection is nontrivial; the discontinuity and nonlinearity of biology makes it difficult to predict
whether a given model will faithfully recapitulate physiology in the domain of inquiry, even
given evidence of "good behavior" in related domains. Of course, pragmatism mandates that we
make such educated guesses in model selection, but it is thus important to understand that any
model alone has unclear relevance to "true" physiology (put in quotations as we are gradually
appreciating significant inter-person variation in physiology, rendering "true" physiology an
elusive notion). Findings made in one model will ideally be coupled with findings made in other
models, as consensus between various model systems is presumably more reliable.
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These concepts of model selection guide model development, the goal of which is to create
models that improve one of the above-mentioned evaluation parameters of models; e.g.
producing a model that captures more of a particular domain of physiology, or a miniaturized
model that is amenable to high-throughput screening. In this thesis, we describe two model
development projects with the former goal - helping virologists study infection phenomena that
were previously intractable with existing models. We focus particularly on the development of in
vitro models; this work runs in parallel to exciting work being performed both in our lab and in
others for the development of animal models for HCV. In vivo models have important pros and
cons relative to in vitro models. They permit an appreciation of complex features for which in
vitro models may be too simplistic, such as systems-scale phenomena across numerous organ
systems, pharmacodynamics and bio-distribution, and off-target effects of interventions; further,
they are central to the current Food & Drug Administration (FDA) paradigm for drug translation.
However, in vivo models are costly, not as easily accessible, not as amenable to experimentation,
and morally questionable. On the other hand, in vitro model systems are relatively cheap and
amenable to high-throughput screening, far more accessible, have greater experimental
flexibility, and generally do not raise ethical questions; as such, they are the staple of most
research programs. The author believes that there is another often under-appreciated advantage
of in vitro models. The thought leader Richard Feynman once said, "What I cannot create, I do
not understand;" to this end, in vitro model systems permit us to more fully understand bio-
systems from a "bottom-up" methodology that will ideally intersect with "top-down" studies
performed in vivo. Conversely, the author also believes that there is an over-cited limitation of in
vitro models. The prevailing view and practice of science and translation almost force us to
believe that in vitro model systems sacrifice a large portion of normal physiology that in vivo
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models "obviously" represent more accurately. However, it is unlikely that this is strictly true for
all or even most bio-systems given that animals may be a poor reflection of human physiology;
that in vitro models at least permit the study of human cells; and that in vitro models enable
manipulation of cells to address very specific questions of interest, easing the interpretation of
findings in these models. The author feels that a more balanced view of the relative roles of in
vitro and in vivo models will be in order; this will be particularly important given that both
governmental and commercial entities are placing increasing fiscal constraints on biomedical
research that may deter significant in vivo experimentation. Progress to this end could benefit
from research aiming to more methodically understand how model systems recapitulate certain
components of physiology but not others, improving our ability to predict the regimes within
which they converge to or diverge from a reasonable approximation of "true" physiology. The
use of tissue engineering and microtechnology tools in developing "human-on-a-chip" models of
physiology is a promising step forward.
1.3.2. Models of hepatitis C virus infection
Because of the narrow species tropism of HCV, the only robust in vivo model system is the
chimpanzee [25], which is very costly, general unavailable, and morally questionable. Recently,
several groups have demonstrated progress in developing humanized mouse models of HCV
infection [26, 27], though these still suffer from general inaccessibility and unreliability. As
such, investigation of HCV in vivo continues to be challenging, forcing many investigations to
remain in vitro.
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This thesis focuses on HCV in vitro model development. In a simple sense, an in vitro model
system for studying viral infection requires two parts - some component of the host, and some
component of the virus. If uniting these two components enables some part of the viral life cycle
to occur, the combination constitutes an in vitro model of HCV infection. Parallel to the
difficulties of studying HCV in vivo, HCV research has undergone a long and tortuous trajectory
of in vitro model development, involving numerous host cell models, viral RNAs, and sources of
virions [23, 28-32]. One major challenge in HCV research has been the notorious challenge
associated with culturing primary hepatocytes [33-36], which has forced researchers to rely on
hepatoma cell lines that dubiously replicate hepatic phenotype, displaying abnormal cell
proliferation, dysregulated gene expression, dysfunctional mitochondria, aberrant signaling, and
abnormal endocytic functions [37-45]. Cultivation of HCV in these cell lines proved difficult,
requiring investigators to utilize transfection of sub-genomic and genomic viral RNAs to observe
any replication. Twenty years after the discovery of HCV [4, 5], research revealed that the
problem was due to the lack of both an appropriate strain of HCV that could replicate in culture
as well as an appropriate cell line - it was only after the coupling of the Huh-7 hepatoma cell line
[46] with the Japanese fulminant hepatitis (JFH)- 1 strain of HCV [47] that a successful model of
the full HCV life cycle was developed [48-50]. The current state-of-the-art model for robust
HCV infection involves the infection by JFH-1 and its derivatives of the particularly permissive
Huh-7.5 sub-line [51], whose unique permissiveness is likely due to defective innate immune
signaling [52]. Unfortunately, despite significant research efforts, it remains unclear why only
JFH-1 and its derivatives are infectious in vitro, and why the Huh-7 hepatoma cell line is
uniquely permissive.
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Though the JFH-1/Huh-7.5 model has proven invaluable to HCV research, it has at least three
major limitations. First, hepatoma cells diverge significantly from primary adult hepatocytes as
described, often rendering it challenging to interpret findings. Further, primary adult hepatocytes
may also be superior for certain therapeutic development applications, as they have more
physiologic absorption, distribution, metabolism, and excretion/toxicity (ADME/tox) properties
[53]. Studying infection in primary adult hepatocytes would only be possible with platforms that
enable primary hepatocytes to maintain their liver phenotype long-term. A second limitation of
the JFH-1/Huh-7.5 model is that because Huh-7.5s are derived from one original donor, they fail
to capture genetic variations between individual people; this forces researchers to contextualize
findings within the background of a single individual. Genome-wide association studies (GWAS)
have demonstrated genetically driven inter-host differences in HCV infection natural history and
treatment response [54-56], but cell culture models that enable the investigation of infection in
different genetic contexts do not exist. As such, it would be ideal to "personalize" the study of
HCV infection. Finally, a third limitation of the JFH-1/Huh-7.5 model is that it cannot be
generalized to the study of non-JFH-1-based strains of HCV. It is recognized that different
strains of HCV can have significant variations in terms of pathogenesis and treatment response
[23], and an ideal model of HCV infection would enable studies of HCV infection broadly.
1.3.3. Assays for hepatitis C virus infection
Infection is a complex process involving the interplay between host and virus, starting at the
subcellular level; host properties shape viral behavior, and viruses in turn modulate the host.
Ideal assays would provide a window into the systems biology of this process. Unfortunately,
existing assays - such as polymerase chain reaction (PCR) for host/viral nucleic acids and
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immunostaining for viral proteins - blindfold researchers in several ways. First, most assays are
suboptimally sensitive and specific, requiring the accumulation of sufficient viral material for
detection, and having poor discrimination between viral positive and negative strands; sensitivity
for HCV assays are especially poor in primary culture systems which have high autofluorescent
background and low infection. Further, they are generally bulk, involving lysis of populations of
cells for quantifying host/viral RNAs or viral proteins and thus sacrificing single-cell
phenomena. Additionally, most assays involve terminal processing and thus do not enable long-
term monitoring of infection behavior [57]. Another limitation is that assays typically do not
yield much information, at best returning quantification of a single parameter. Access to tools
that overcome these limitations will prove invaluable in better elucidating host-virus interactions,
and quantitative, multi-parametric data in general will help advance our understanding of
infection through mathematical modeling.
1.4. Advances in cell sourcing, tissue engineering, and high-content imaging
1.4.1. Advances in hepatocyte sourcing
Hepatocytes can proliferate in vivo [58-61], but despite extensive research, human hepatocytes
have not been made to proliferate in vitro. Because human hepatocytes are necessary for the
investigation of human hepatotropic pathogens such as HCV which have a narrow species
tropism, and because it is not practically feasible to obtain sufficiently large quantities of adult
hepatocytes from a single human host, alternative strategies are being pursued to source in vitro
liver modeling. Advances in stem cell research are one promising avenue for hepatocyte
sourcing. Functional hepatocyte-like cells have been obtained from embryonic stem cells [62-
68], fetal and adult progenitor cells [69-75], and extra-hepatic stem cells and progenitors [76]. A
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major recent advance is the discovery that expression of certain transcription factors in
"terminally" differentiated cells induces reprogramming into pluripotent cells, known as induced
pluripotent stem cells (iPSCs) [77-81]; these iPSCs can in turn be directed towards hepatocytes
[82-84]. This raises the exciting possibility of obtaining virtually limitless hepatocytes in the
same way as ES cells, with the exciting added advantage of being able to produce person-
specific hepatocytes from arbitrary individuals of diverse genetic backgrounds. This feature will
be employed in the efforts to "personalize" the study of HCV infection described in this thesis.
1.4.2. Advances in in vitro liver model development
Since its inception as a field [85], tissue engineering has broadened in scope to be appreciated as
the use of the tools, methods, and analyses of classic engineering to engineer cellular constructs
for both regenerative medicine as well as models of physiology and pathophysiology. Classic
model development by basic biologists has typically involved random, two-dimensional
cultivation of cell types. While this has proven fruitful for a vast body of research, the
application of tissue engineering to developing more complex models has broadened the range of
biological phenomena we can recapitulate in vitro [86-88].
Particularly relevant to this thesis is the in vitro modeling of liver. Given the challenge associated
with cultivating primary hepatocytes in vitro [33-36], researchers have employed numerous
alternative liver platforms including perfused whole organs, wedge biopsies, and precision-cut
liver slices [36, 89, 90]; purified liver fractions and single enzyme systems [91, 92]; and cell
lines from hepatoblastomas or immortalization of primary hepatocytes [93-96]. However, since
primary hepatocytes are the ideal platform, many efforts have been made to stabilize their
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phenotype in vitro, initially by manipulating three basic parameters: culture medium,
extracellular matrix, and heterotypic interactions with non-parenchymal cells. Researchers have
used serum-free culture medium preparations [97]; culture medium supplemented with serum,
physiological factors such as hormones and amino acids [33, 98, 99]; non-physiologic factors
such as phenobarbital and dimethylsulfoxide [100, 101]; and medium with elevated oxygen
tension [102]. Extracellular matrix and alternate surface chemistries, both in monolayer or gel
configurations, have been utilized to control attachment and maintain hepatocyte phenotype by
presenting specific biological and mechanical stimuli [33, 103-110]. Finally, co-culture with
nonparenchymal cells has successfully been used to provide hepatocytes with heterotypic
interactions that preserve their liver phenotype [45, 111]. Aside from such two-dimensional
culture schemes, it is possible to manipulate primary hepatocytes such that they aggregate into
three-dimensional spheroids on various surfaces upon which they can be cultured with improved
longevity [33, 104, 112-126]; alternatively, spheroids can be encapsulated to control cell-cell
interactions [127-130]. Numerous bioreactor cultures of hepatocytes and hepatocyte aggregates
have also been developed, with advanced features such as fluid flow, precise control over culture
parameters, and recapitulation of liver nutrient and oxygen gradients [34, 36, 131-140].
A major advance in the development of in vitro model systems is the manipulation of cell-cell
and cell-matrix interactions using microtechnology tools adopted from the semiconductor
industry [141-145]; these tools also enable miniaturization of assays [146], studies with dynamic
control of stimuli [145, 147], and assembly of complex cellular structures [148, 149]. Our lab has
used micropatterning methods to control the balance between homotypic and heterotypic
interactions in primary hepatocyte co-cultures with nonparenchymal stromal cells [45, 150]; the
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resulting micropatterned co-cultures (MPCCs) provide long-term expression of liver-specific
functions, and is the basis of the primary hepatocyte HCV model development efforts described
in this thesis.
1.4.3. Advances in high-content imaging
The increasing sophistication of imaging and downstream image analysis are giving rise to
assays that simultaneously reveal many kinds of information about bio-systems of interest; these
high-content or multi-parametric imaging modalities are powerful tools for accelerating biology
and enabling high-throughput screening [151-157]. One class of such technologies is imaging
methods for quantitatively assessing the molecular composition of single cells, in turn
illuminating inter-cell biochemical and phenotypic heterogeneity [158-162]. As RNA viral
genomes are central to the infect by RNA viruses such as HCV, and because host gene
expression can be viewed at the messenger RNA level, we are particularly interested in imaging
assays that could overcome limitations of existing assays in the detection of RNA. A relatively
recent breakthrough in RNA imaging is quantitative single-molecule RNA imaging [163-172].
Through experimentally facile methods and standard epifluorescence microscopy, it is possible
to visualize single molecules of RNA, allowing single-cell quantification and RNA localization;
it is also possible to multiplex numerous RNA species simultaneously, synergistically enhancing
the information obtained [173]. In this thesis, we will use single-molecule RNA imaging in our
efforts to develop an infection assay that better reveals the host-side of infection.
34
1.5. Thesis overview
The overall goal of our research is to enable investigators to better understand the host-virus
interactions in HCV infection. The state-of-the-art model systems and assays for studying HCV
in vitro suffer from several limitations as described. In this thesis, we employ advances in cell
sourcing, tissue engineering, and high-content imaging to provide technological solutions to
these problems. Further, we demonstrate the value of these platforms by exploring innate
immune signaling, an aspect of host-virus interactions for which existing tools have been
particularly limiting. The technologies developed here address questions that can be
conceptualized at three progressively smaller size scales (Figure 1-2). First, we describe a
"personalized" in vitro model of HCV infection that can be used to elucidate inter-host variations
in infection. We then develop a primary hepatocyte model for HCV infection that we use to
understand how innate immune signaling in the liver controls viral infection. Finally, we detail a
quantitative imaging assay for, studying the intercellular heterogeneity of viral infection. We
conclude with perspectives and future directions for these projects.
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Personalizing the study of
viral infection (Chapter 2)
Studying immune control of infection
using an engineered liver model (Chapter 3)
Illuminating intercellular heterogeneity of
viral infection (Chapter 4)
Figure 1-2. Thesis overview: addressing questions of host-virus interactions at three
size scales. At the person size scale, we develop a technological solution to
understanding differences in infection between individual people. We then create a model
to understand the organ-scale question of how liver immunity controls hepatotropic
infection. Finally, we describe an imaging assay for capturing the cellular
compartmentalization of virus among individual host cells and the host gene expression
interplay with the virus.
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Chapter 2. Personalizing the study of viral infection
2.1. Introduction
Human pathogens impact patient well-being through complex host-pathogen interactions.
Despite the importance of host genetics in this interplay, in vitro model systems for studying the
role of host genetic variation in infection are often unavailable due to tissue scarcity and
challenges in primary culture. The discovery of cellular reprogramming and the ability to
generate host- and tissue-specific cells from induced pluripotent stem cells (iPSCs) have the
potential to transform the study of development, infectious disease, and degenerative disorders
[174, 175]. For example, iPSCs have been used for the mechanistic study of a variety of cells
types implicated in a wide diversity of disease (e.g. Friedreich's ataxia, long QT syndrome,
LEOPARD syndrome, Rett syndrome, and alpha-1 antitrypsin deficiency) [176-180]. However,
no iPSC models of any infectious disease have been reported to date. In this study [181], we
describe the use of iPSC-derived hepatocytes as a model system for studying host-pathogen
interactions for the hepatitis C virus.
Afflicting over 170 million worldwide, hepatitis C virus (HCV) is a prototypic pathogen for
which host genetic factors have been implicated in modulating disease natural history and
treatment response but whose functions remain poorly understood due to the lack of robust
experimental systems. For example, genome-wide association studies have identified host
polymorphisms in the interleukin-28B (IL-28B) locus that correlate with spontaneous HCV
clearance and viral response to interferon-based therapy [54]. Additionally, individuals with
mutations in genes that are critical for HCV entry (e.g. LDLR, CD81, SRBI, CLDN1), assembly
(ApoE, ApoB), or immune response (STATi) have been described [54, 182-186]. Despite our
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awareness that host genetics impacts viral pathogenesis in such individuals, the mechanistic basis
for these correlations remain unclear due largely to the lack of a robust experimental system
incorporating host cells with these genetic backgrounds. The development of an iPSC-derived
HCV model has the potential to further elucidate the role of these host factors on disease
pathogenesis.
2.2. Results and discussion
2.2.1. Induced pluripotent stem cell-derived hepatocyte-like cells (iHLCs) express HCV
host factors
To test the hypothesis that iPSC-derived differentiated cells are permissive to infection, we
sought to model hepatitis C virus infection (Figure 2-1). HCV infects human hepatocytes, and
we have recently demonstrated the directed differentiation of human iPSCs into hepatocyte-like
cells (iHLCs) [82]. iHLCs routinely demonstrate an expected cobblestone morphology (Figure
2-2A, left), and over 80% express both albumin and HNF-3p (Figure 2-2A, right). In addition,
iHLCs secrete liver-specific serum proteins such as albumin and alpha 1-antitrypsin at levels
15% and 50% respectively of those of primary human hepatocytes maintained in long-term
culture models [187] (Figure 2-2B, bottom). Here, we investigated whether iHLCs express host
genes important for HCV infection ("host factors"), are capable of supporting the HCV life
cycle, and respond to infection with an appropriate antiviral inflammatory response. We found
that iHLCs express known HCV host factors including the liver-specific microRNA-122 (Figure
2-2B) and entry factors (CD81, SRBI, claudin-1, and occludin) (Figure 2-2C,D); analysis of
iPSC and iHLC transcriptional microarrays [82] confirmed that host factors previously identified
in an shRNA screen [188] were enriched in iHLCs, and expressed to a greater extent in iHLCs
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than iPSCs (Figure 2-2E). Although iHLCs exhibit many adult hepatocyte characteristics, their
expression of phase 1 and phase 2 enzymes (high CYP3A7, CYP7A1, and GSTA4 and low
CYP2C family gene and CYP3A4 gene expression) and coexpression of alpha-fetoprotein and
albumin is collectively more consistent with that of a fetal hepatocyte [82, 189, 190].
Experimental evidence suggests that iPSC are fully capable of differentiating into terminally
differentiated adult hepatocytes as demonstrated in mouse IPS tetraploid complementation
experiments and in mouse and human iHLCs transplantation experiments [82]; however, culture
conditions have not yet been established that allow for terminal differentiation.
Host of interest HCV patient
Induced pluripotent Genotype 2A
stem cells (iPSCs) HCV isolate
iPSC-derived hepatocyte- Chimeric luciferase
like cells (iHLCs) reporter HCV
Personalized model of HCV infection
Figure 2-1. Personalized HCV infection model. Induced pluripotent stem cell-derived
hepatocytes from one donor are infected with HCV from another.
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Figure 2-2. Induced pluripotent stem cell (iPSC)-derived hepatocyte-like cells
(iHLCs) express known hepatitis C virus (HCV) host factors. (A) (Left) Phase image
of iHLCs. Scale bar = 100 pm. (Right) Immunofluorescence imaging of iHLCs for
albumin (red), HNF-3p (green), and DAPI (blue). Scale bar = 90 pm. (B) Quantification
of liver-specific factors in iHLCs. microRNA-122 expression blot (for two typical
batches of iHLCs, A and B) and quantification by qPCR. Adult human hepatocytes [187]
included as a reference. Albumin (Alb) and alpha 1-antitrypsin (A1AT) secretion by
iHLCs as measured by ELISA. Error bars show s.d. (C) (Left) Immunofluorescence
imaging of iHLCs for HCV entry factors scavenger receptor BI (SRBI) (red) and CD81
(green), with DAPI co-staining (blue). Scale bar = 40 pm. (Right) Immunofluorescence
imaging of iHLCs for HCV entry factors occludin (OCLN) (red) and claudin 1 (CLDN)
(green), with DAPI co-staining (blue). Scale bar = 40 pm. (D) Western blot for HCV
entry receptors CD81, SRBI, CLDN, and OCLN, in two typical batches of iHLCs (A and
B) in duplicate samples. (E) Relative expression of HCV host factors [188] by three
batches of iPSCs and iHLCs as determined through gene microarray [82] (A, B, and C).
Host factors organized by gene ontology (GO) biological process terms, including repeats
for genes associated with multiple terms.
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2.2.2. HLCs support the entire life cycle of hepatitis C virus
To assess HCV replication in iHLCs, we used JFH-1, a genotype 2a HCV reporter virus
expressing secreted Gaussia luciferase (GLuc) [191]. Persistent elevation of GLuc signal was
observed in infected cultures above uninfected ("mock") control (Figure 2-3A, top); further,
initiating daily treatment with either the HCV NS5B replicase inhibitor 2'-C-methyladenosine
(2'CMA) or the NS3/4A protease inhibitor VX-950 (telaprevir) 7 days post infection (dpi)
rapidly abolished GLuc production (Figure 2-3A, top). Further, qRT-PCR on iHLC lysates 14
dpi showed that HCV genomes were significantly more numerous in the absence of antivirals
(Figure 2-3B), consistent with the GLuc assay. In addition, using a real-time fluorescence
reporter of infection [192], we confirmed HCV protease activity in infected iHLCs (Figure
2-3C). Together, these results indicate ongoing HCV replication in infected iHLCs. To verify
that infected iHLCs produce infectious virions and thus recapitulate the entire viral life cycle,
culture supernatants were passaged 13 dpi onto uninfected Huh-7.5 cells which are highly
permissive to HCV and thus allow sensitive detection of infectious virions [48]. As shown by
GLuc production and HCV NS5A staining (Figure 2-3A, bottom), supernatants from infected
iHLCs carried infection to Huh7.5s. Thus, iHLCs support the complete HCV life cycle including
replication and release of infectious virions. Therefore iHLCs sustain the entire HCV viral life
cycle of at least genotype 2a, consistent with prior reports that have shown that human fetal
hepatocytes are capable of sustaining the hepatitis C viral life cycle [193, 194]. Future work
towards a fully personalized in vitro model of HCV infection would incorporate both
personalized hepatocyte-like cells as well as HCV patient isolates, including the most HCV
common genotype la.
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Figure 2-3. iPSC-derived hepatocyte-like cells (iHLCs) as a model for hepatitis C.
(A) iHLC cultures were either infected with HCV reporter virus expressing secreted
Gaussia luciferase (GLue) (n= 18) or mock infected (n=6), and subsequently sampled and
washed daily. After 7 days (solid gray arrow), infected iHLCs were treated with NS5B3
polymerase inhibitor 2'CMA (n=6), NS3/4A protease inhibitor VX-950 (n=6), or vehicle
DMSO (n=6). Drug treatment was discontinued 12 dpi, and supernatants collected after
an additional day of culture were assayed for the presence of infectious virus by passage
onto Huh-7.5s. Medium from Huh-7.5 cells was harvested 5 days post passage for GLuc
assay. (Top) GLuc secretion by iHLCs. RLU = relative light units. DMSO- vs. 2'CMA-
treated cultures was statistically significant: *p < .05, ***p < .001 (one way ANOVA
with Tukey post test). (Bottom) GLuc secretion by Huh-7.5s after passage of iHLC
supernatants. DMSO vs. mock was statistically significant: ***p < .001 (one way
ANOVA with Tukey post test). NS5A staining of infected Huh-7.5s post passage. Scale
bar = 50 pm. (B) iHLCs were lysed 14 dpi. Copies of HCV RNA in lysates were
quantified by qRT-PCR. DMSO vs. 2'CMA was statistically significant: ***p < .001
(one way ANOVA after log transformation with Tukey post test). (C) NS3/4A activity
imaging of HCV-infected iHLCs [191]. Cells in image delimited by lines (white =
uninfected, red = infected). Scale bar = 25 pmn. Data in A-C are means, error bars show
s.d.
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2.2.3. HCV infection induces an antiviral inflammatory response from iHLCs
We next determined whether infection induces an antiviral inflammatory response, which is
central to the natural history of clinical disease progression but defective in existing in vitro
models of HCV [52]. qRT-PCR on iHLC lysates 2 or 14 dpi revealed that expression of
inflammatory markers was upregulated by infection (Fig. 4A), and ELISA on culture
supernatants 14dpi verified persistent TNF-a secretion as a result of infection (Fig. 4B). These
results are characteristic of an ongoing inflammatory response in cells with an intact innate
immune axis. Notably, IL-28B, whose gene variation predicts response to hepatitis C treatment
in GWAS studies [54], was expressed in response to viral infection 2 dpi but declined over two
weeks, underscoring the potential for such a platform to provide clinically relevant insights.
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Figure 2-4. iPSC-derived hepatocyte-like cels (iHLCs) demonstrate an
inflammatory response to hepatitis C virus infection. (A) mRNA expression of innate
immune/inflammatory markers in lysates of infected, DMSO-treated iHLCs relative to
mock at 2 and 14 dpi as determined by qPCR. (B) TNF-a secretion by HCV- and mock-
infected iHLCs 14dpi as determined by ELISA. Difference was statistically significant:
*p < .05. Data in A and B are means, error bars show s.d.
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Existing model systems to study host genetics, such as polymorphisms in IL-28B, are limited to
needle biopsies, surgical resection, organ donation and hepatoma cell lines of a single
background. We believe that this study lays the foundation for 'personalized' in vitro models that
can capture genetic variation of both host and pathogen whereby iPSCs can be generated from
identified patients with known or unknown genetic defects that impact infection. In this study,
we report that hepatocyte-like cells derived from iPSCs support the entire life cycle of hepatitis
C virus including inflammatory responses to infection but we believe that in the future, patient
derived iHLCs will serve as a new model system to probe the basis of hepatitis viral
pathogenesis and can ultimately be extended to other pathogens and tissue systems. Such models
will advance our understanding of host-pathogen interactions and help realize the potential of
personalized medicine.
2.2.4 Personal contributions to this work
The author of this thesis planned, performed, and interpreted experiments in an equal
collaboration with his colleague Dr. Robert Schwartz.
2.3. Materials and methods
Induced pluripotent stem cell culture and hepatocyte-like cell generation
Undifferentiated iPSC were maintained and differentiated into hepatocyte-like cells (iHLCs) as described [82]. In
brief, iPSCs were cultured in monolayer on Matrigel (Becton Dickinson) and directed differentiation was achieved
by sequential exposure to Activin A, BMP4, bFGF, HGF, and OSM.
HCVcc preparation, infection, luciferase assay, antiviral drugs, and NS3/4A activity imaging
As described [191], Gaussia luciferase expressing reporter virus Jc lFLAG2(p7-nsGluc2A) stocks were prepared by
electoporating in vitro transcribed RNA into Huh-7.5 cells, collection of supernatant, and filter concentration. Fifty
percent tissue culture infectious dose (TCID5o) was determined by titrating on Huh-7.5s to be 107 TCID50/mL. These
stocks were diluted lOx in serum-free, OSM-containing medium and used to inoculate iHLCs for 24h. Cultures were
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washed with serum-free medium and propagated in OSM-containing medium. Supernatants were collected and
frozen at -80C daily for luciferase quantification. To demonstrate drug-sensitive HCV infection, HCV NS5B
polymerase inhibitor 2' C-methyl-adenosine (2'CMA) (EC50=27 nM) and NS3/4A protease inhibitor VX-950
(telaprevir) (EC50=400 nM) were added to culture medium at 50*EC50 and 25*EC50, respectively, at final 0.1%
DMSO. 2'CMA was the gift of Drs. D. Olsen and S. Carroll (Merck Research Laboratories, West Point, PA) and
also obtained from Carbosynth Limited. VX-950 was obtained from Alembic Limited. Real-time fluorescence
reporter of HCV infection by monitoring NS3/4A protease activity was performed as described. Briefly, lentivirus
carrying the reporter was used to transduce iPSCs. Infection was carried out five days later, and protease activity
was assayed 7 days post infection.
Huh-7.5 culture and infection transmission assay
Huh-7.5s were propagated in a DMEM with L-glutamine (Cellgro)-based medium containing 100 U/mL penicillin
and 100 ug/mL streptomycin (Cellgro), and 10% FBS (GIBCO). To test if infected iHLCs produced infectious
virions, iHLCs were placed in OSM-containing medium without supplementation with antivirals. Supernatants
collected 1 day later were used to inoculate Huh-7.5 cells. After overnight incubation, cells were washed and placed
in Huh-7.5 medium for 48h before being washed again. On day 5 post-inoculation, supernatants were assayed for
luciferase as described [191]. To assess NS5A antigen expression, Huh-7.5 cells were fixed in methanol,
counterstained with Hoechst (Invitrogen), and immunostained with mouse anti-NS5A (9E10) and goat-anti-mouse
Alexa Fluor 594 (Invitrogen).
RT-PCR for detection of cytokines and HCV RNA
Total RNA was isolated with RNeasy Plus Mini Kit (Qiagen, Valencia, CA). First-strand cDNA was synthesized
using Moloney murine leukemia virus (M-MLV) reverse transcriptase (Biorad). Quantitative PCR for cytokines was
carried out with Taq polymerase and SYBR Green in supplier's reaction buffer containing 1.5 mMV MgCl2 (Biorad).
Oligonucleotide primer sequences are available by request. Amplicons were analyzed by 2% agarose gel
electrophoresis. Quantitive PCR on HCV genomes was performed as described [191].
Immunofluorescence analysis for hepatic gene expression and host factor expression
iHLCs were fixed in four percent paraformaldehyde and/or -20oC methanol. Following washing and blocking in
0.1% donkey serum/0. 1% Triton X- 100 in PBS, cells were incubated in primary antibody overnight at 4C: mouse
anti human albumin (Sigma-Aldrich), rabbit anti HNF-3p (Santa Cruz Biotechnology), mouse anti-human CD81
(Becton Dickinson), rabbit anti-CLDN1 (Invitrogen), rabbit anti-SCARB 1 (Novus Biologicals), mouse anti human
Occludin (Invitrogen). Secondary antibodies were donkey anti mouse DyLight 594-, donkey anti rabbit DyLight
488-, donkey anti mouse DyLight 488-, and donkey anti rabbit DyLight 594-conjugates and counterstained with
Hoescht dye (Invitrogen).
Western blot for entry receptors
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Total protein was extracted with RIPA lysis buffer, and samples were separated by electrophoresis on 12%
polyacrylamide gels and electrophoretically transferred to a polyviylidene difluoride membrane (Bio-Rad
Laboratories). Blots were probed with mouse anti-human CD81 (Millipore), rabbit anti-SCARB1 (NB110-57591,
Novus Biologicals), rabbit anti-CLDN1 (51-9000, Invitrogen), and rabbit anti-occludin (40-4700, Invitrogen),
followed by horseradish peroxidase-conjugated secondary antibodies, and developed by SuperSignal West Pico
substrate (Thermo Scientific).
miR-122 analysis
Total RNA was isolated with miRNeasy Mini Kit (Qiagen). miRNAs were polyadenylated by poly(A) polymerase
and cDNA was synthesized using miScript PCR kit (Qiagen). Quantitative real-time PCR on miR-122 was then
performed using hsa-miR-122 specific primer (Qiagen) and normalized to RNU6B (Qiagen). Standard curves were
performed to obtain absolute levels with synthetic miR-122 (Dharmacon).
Albumin and alpha 1-antitrypsin ELISA
Spent medium was stored at -20 'C. Alpha-1-Antitrypsin and albumin media concentrations were measured using
sandwich ELISA technique with horseradish peroxidase detection (Bethyl Laboratories) and 3,3',5,5'-
tetramethylbenzidine (Thermo Scientific) as a substrate.
Microarray analysis and host factor expression
Microarray analysis was performed as described4 . Microarray profiles on iHLCs (http://www.ncbi.nlm.nih.gov/geo/
accession number GSE14897) were analyzed using gene set enrichment analysis v2.0 with a list of previously
identified HCV host factors6. Enriched genes were determined by random permutation of gene sets and a p-
value<0.05. Gene ontology terms and gene associations were obtained using Gene Set Analysis Toolkit v2.
Statistical analysis was performed using a hypergeometric distribution to identify terms enriched with two genes and
ap-value <0.05, and then connected in a tree hierarchy [195].
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Chapter 3. Studying immune control of infection using an
engineered liver model
3.1 Introduction
Hepatitis C virus (HCV) remains a major public health problem, affecting approximately 130
million people worldwide. HCV infection can lead to cirrhosis, hepatocellular carcinoma, and
end-stage liver disease, as well as extrahepatic complications such as cryoglobulinemia and
lymphoma. Preventative and therapeutic options are severely limited; there is no HCV vaccine
available, and nonspecific, interferon (IFN)-based treatments are frequently ineffective.
Development of targeted antivirals and the advancement of HCV basic biology have been
hampered by the lack of robust HCV cell culture systems that reliably predict human responses.
The recent advancement of the HCV cell culture (HCVcc) system [48] has enabled recapitulation
of the entire HCV life cycle in human hepatoma cells. Despite the demonstrated value of these
models to HCV research programs, these cell lines differ significantly from the natural primary
hepatocyte host for HCV, displaying abnormal proliferation, deregulated gene expression, as
well as aberrant signaling and endocytic functions [37-40]. Consequently, neither the
perturbation of normal hepatocyte biology by infection, nor authentic host responses to HCV,
can be studied accurately in culture [37]. Primary hepatocytes are considered a more
physiologically relevant system, but are notoriously difficult to maintain in culture as they
precipitously decline in viability and phenotype upon isolation from their in vivo
microenvironment [45]. This rapid deterioration, as well as the lack of HCV detection methods
with high specificity and sensitivity, has made it difficult to assess viral replication in primary
human cell cultures [193, 196-200]. Over the last few decades, investigators have employed a
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plethora of different strategies to preserve liver-specific functions in vitro and to extend the
lifetime of liver model systems [150]. These strategies typically include extracellular matrix
manipulations, defined culture media, fluid flow using bioreactors, or alteration of cell-cell
interactions by forming three-dimensional (3D) spheroidal aggregates or co-cultivating with
nonparenchymal cell types [34, 45, 121, 150]. Although some of these models provide necessary
extracellular matrix cues, they lack crucial heterotypic cell-cell interactions and control over
tissue architecture, both of which are known to affect liver-specific functions [45, 150]. Further,
in culture techniques using fragile extracellular matrix gels, 3D aggregates, and/or continuous
perfusion, scaling down to 96-well and smaller formats appropriate for drug screening remains
challenging. Most importantly, it is unclear whether any of these model systems support
persistent HCV infection.
First [201], we show the entire HCV life cycle recapitulated in micropatterned co-cultures
(MPCCs) of primary human hepatocytes and supportive stroma in a multiwall format. MPCCs
form polarized cell layers expressing all known HCV entry factors, and sustain viral replication
for approximately two weeks. When coupled with highly sensitive fluorescence- and
luminescence-based reporter systems, MPCCs have potential as a high-throughput platform for
simultaneous assessment of in vitro efficacy and toxicity profiles of anti-HCV therapeutics.
Second, we address the question of why infection is resolved after only two weeks, a finding in
our system that deviates from the expectation of a chronic virus. In particular, we test the
hypothesis that IFN signaling controls HCV infection in MPCCs. The Huh-7.5 hepatoma cell
line [51] used by most investigators suffers from numerous deficiencies including an inhibitory
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mutation in RIG-I [52] that incapacitates IFN signaling; indeed, this may explain the robust
infection observed in this model. By contrast, natural primary hepatocytes should be capable of
mounting an innate immune response to infection. We show that IFN signaling constrains
infection, leading to acute resolution of infection in MPCCs after two weeks. Inhibition of IFN
signaling rescues the robust and chronic infection characteristic of infection in vivo. Finally, we
show that a cytokine normally present in the liver microenvironment, interleukin-6 (IL-6),
"tolerizes" hepatocytes to infection by inhibiting several components of the IFN/signal
transducer and activator of transcription (STAT1) signaling pathway. As such, a refined MPCC
model dosed with IL-6 recapitulates the more robust infection normally observed in vivo. These
findings have implications for the mechanistic basis behind viral persistence in vivo.
3.2 Results and discussion
3.2.1. Primary human hepatocytes in micropatterned co-cultures form polarized cell layers
and support HCV glycoprotein-mediated entry
We have recently developed a miniaturized, multi-well model of human liver tissue with
optimized microscale architecture that maintains phenotypic functions for several weeks in vitro
[150]. In this cell culture system, primary adult human hepatocytes do not seem to proliferate.
Primary hepatocytes are organized into micropatterned colonies of empirically optimized
dimensions, and subsequently surrounded by supportive stroma (Figure 3-1, Figure 3-2a,b).
Here, we show that primary human hepatocytes form polarized cell layers in MPCCs. Multidrug
resistant protein 2 (MRP2), zona occludens protein 1 (ZO1), and HCV entry factors claudin-1
(CLDN1) [202] and occludin (OCLN) [203, 204], were located in the canalicular domain of tight
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Figure 3-1. Micropatterned co-cultures (MPCCs) of human primary adult
hepatocytes and supportive stroma. Progressively magnified phase images of
hepatocytes in micro-patterned co-cultures (islands 500 9m in diameter).
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Figure 3-2. Primary human hepatocytes in MPCCs form polarized cell layers,
express HCV entry factors, and support HCV glycoprotein-mediated entry. Bright
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field images of primary hepatocytes in MPCCs (a) and in mono-cultures (b). Wide-field
fluorescence images of fixed MPCCs stained for the canalicular marker multidrug
resistance-associated protein 2 (MPR2) (c), and the basolateral marker CD26 (d). Nuclear
(blue) and antigen-specific staining (green) for CD81 (e), scavenger receptor class B
member 1 (SCARBI) (f), claudin 1 (CLDN1) (red) (g), and occludin (OCLN) (h) in
MPCCs. (i) Merged image of primary hepatocytes stained for MRP2 (green), zona
occludens protein 1 (ZO1) (red), and nuclei (blue). (j) 3D rendering of boxed area in (i).
(k) Infection of MPCCs with retroviral pseudoparticles bearing HCV glycoproteins
(HCVpp), vesicular stomatitis virus glycoprotein (VSVGpp), or no glycoproteins (Env-
pp), and containing an enhanced green fluorescent protein (EGFP) reporter gene.
Representative images are shown for all experiments. (1) Anti-CD81 antibody blocks
entry of HCVpp (dark bars), but not VSVGpp (white bars). Concentrations of antibody
(pg/mL) are noted. Mean and s.d. are shown. Scale bars: 100 pm (a, b, k), 50 gm (c, d),
20 pm (e-i).
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Figure 3-3. HCV entry factor staining in normal human liver. Wide-field
fluorescence images of fixed sections of human liver from normal uninfected donors
stained nuclei (blue in merged image) and antigen-specific staining (green in merged
image) for CD81 (Upper), SCARBI (Middle) and CLDN1 (Lower). Scale bars: 30 pm.
junction (TJ)-like structures, whereas CD26 was localized on the basolateral domain (Figure
3-2). The presence of bile canalicular structures between adjacent hepatocytes was confirmed via
3D renderings of ZO1 and MRP2 (Figure 3-2ij). Compared to human liver tissue, primary
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hepatocytes in MPCCs expressed similar patterns of HCV entry factors CD81 [205], scavenger
receptor class B type 1 (SCARB 1) [206], and CLDN 1 [202] (Figure 3-2, Figure 3-3).
To test whether MPCCs support HCV glycoprotein-mediated entry, we infected cultures with
HCV pseudoparticles (HCVpps). HCVpp, which are defective lentiviral particles that display the
HCV El and E2 envelope glycoproteins, and encode an enhanced green fluorescent protein
(EGFP) reporter gene, allow rapid quantification of infection in the absence of replication.
Approximately 1-3% of the human hepatocytes in MPCCs, but none of the supporting murine
embryonic fibroblasts (3T3-J2), could be infected with HCVpp (Figure 3-2k,1). Pseudoparticles
lacking glycoproteins did not infect the cultures, although MPCCs were readily infected by
pseudoparticles displaying the pan-tropic vesicular stomatitis virus glycoprotein (VSVGpp). A
blocking antibody targeting CD81 completely abrogated HCVpp infection but not VSVGpp
infection, consistent with HCV-specific dependence on CD81 (Figure 3-21).
3.2.2. HCV persistent replicates in primary human hepatocyte MPCCs
Despite considerable effort, it has not been possible to unequivocally demonstrate HCV
replication in primary hepatocyte cultures over prolonged periods of time. Previous studies have
relied on quantifying HCV RNA by quantitative reverse transcription polymerase chain reaction
(qRT-PCR), a technique that cannot be convincingly used for detecting rare infectious events due
to the high background of nonspecifically bound viral RNA. We instead employed a highly
sensitive HCVcc reporter virus expressing secreted Gaussia luciferase (Gluc), JclFLAG2(p7-
nsGluc2A) [207]. After inoculation, cultures were washed to remove Gluc carryover, and
luciferase secretion was monitored as an indicator of viral replication. We found that several
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conventional culture systems - pure hepatocytes on adsorbed collagen, collagen gel sandwich,
Matrigel overlay, and randomly distributed co-cultures - could not sustain HCV replication,
presumably due to a decline in liver-specific phenotype (Figure 3-4) [150]. In contrast, MPCCs
in multi-well formats supported HCV replication for at least two weeks (Figure 3-5A, Figure
3-6). Treatment with HCV nonstructural protein 3/4A (NS3/4A) protease inhibitor ITMN191,
nonstructural protein 5B (NS5B) polymerase inhibitor (2'CMA), or IFN-a reduced luciferase
activity to background levels (Figure 3-5A), indicating that persistent signal was indeed due to
ongoing viral replication. Persistent HCV infection was achieved in MPCCs created from freshly
isolated or cryopreserved human hepatocytes from several donors, reflecting the reproducibility
of the optimized microscale architecture and the concomitant phenotypic stability. We next
attempted to quantify HCV RNA and proteins in MPCCs by qRT-PCR, immunofluorescence,
and Western
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Figure 3-4. Primary hepatocytes in MPCCs maintain HCVcc infection over longer
periods of time than conventional hepatocyte systems. Conventional, pure hepatocyte
cultures, widely used in the pharmaceutical industry, and MPCCs were created from the
same donors. Conventional cultures were infected with HCVcc within 24 h of plating,
whereas MPCCs were infected once they achieved functional stability (6 days after
plating). Luciferase activity in supernatants was monitored over 2 weeks post-infection.
One representative time point (6-12 days post-infection) is shown. Luciferase activity is
expressed as percent of mock control.
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Figure 3-5. Primary human hepatocyte MPCCs are susceptible to HCV. (A)
Persistent infection of primary human hepatocytes with HCVcc. Primary hepatocytes in
MPCC were infected with JcFLAG2(p7-nsGluc2A). After 24 h, virus was removed and
MPCC medium containing DMSO (0.1%) or the indicated inhibitors was added. All
inhibitors were used at approximately 50x IC50 (polymerase inhibitor 2'CMA = 2.16
mM, protease inhibitor ITMN191 = 0.16 mM, IFN-a = 500 U/mL). Samples were taken
daily and the media replaced with washing every 48 h. Accumulated luciferase activity in
the supernatants is plotted. Arrows indicate the addition of fresh inhibitor. (B)
Visualization of HCV infection in primary human hepatocytes. MPCCs were transduced
with lentiviruses expressing wild-type (wt) or mutant (C508Y) RFP-NLS IPS HCV
reporter. 24 h after transduction, MPCCs were infected with JclFLAG2(p7-nsGluc2A) or
plasma from HCV-infected patients in the presence of heparin (5 IU), CaCl2 (9 mM), and
MgCl2 (6 mM). 12 h post-infection, virus was removed and MPCC medium was added.
Un-fixed MPCCs were imaged by wide-field fluorescence microscopy at 48 h
postinfection. Representative pseudo-colored fluorescent images are shown; white arrow
heads show nuclear RFP, indicative of HCV infection. Scale bar: 20 pn.
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Figure 3-6. Miniaturized 96-well primary hepatocyte MPCCs. (A) MPCCs were
created in off-the-shelf tissue culture polystyrene plates in formats up to 96-well plates
using soft lithographic techniques. (B) Each well of a 96-well plate contains 14-15
islands of hepatocytes that are 500 pm in diameter and spaced 1200 Pm apart (center-to-
center), and (C) surrounded by 3T3-J2 murine embryonic fibroblasts to create MPCCs.
Scale bars: 2 cm (a), 4 mm (b), 100 sm (c).
blot. In contrast to recent reports [200], we were unable to obtain specific signals above
background, reminiscent of failed attempts to detect HCV proteins in infected liver biopsies,
probably due to the low number of HCV RNA copies per cell [208].
To demonstrate that HCV actively replicates in the primary hepatocyte component of the
MPCCs, we made use of a recently developed fluorescence-based live cell reporter [192]. This
system uses a reporter (RFP-NLS-IPS) composed of a red fluorescent protein (RFP), an SV40
nuclear localization sequence (NLS), and a C-terminal mitochondrial targeting domain (IPS)
derived from the IFN-s promoter stimulator 1 protein (IPS-1), a known cellular substrate for the
HCV NS3/4A protease. The RFP-NLS-IPS substrate was stably expressed in primary hepatocyte
MPCCs (Figure 3-5B). In HCV-infected cells, RFP-NLS-IPS processing by NS3/4A results in
translocation of the cleavage product, RFP-NLS, from mitochondria to the nucleus. This
redistribution of fluorescence was detected in approximately 1-5% of hepatocytes in infected
MPCCs transduced with wild-type RFP-NLS-IPS; no re-localization was detected after infection
of MPCCs harboring a cleavage-resistant reporter (C508Y) or in supporting fibroblasts (Figure
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3-5B). At very low frequency (approximately 1 in 30,000 cells), we also detected RFP-NLS-IPS
cleavage in MPCC cultures infected with plasma or sera from HCV-infected patients (Figure
3-5B).
3.2.3. Primary hepatocytes in MPCCs produce infectious virus
To determine whether primary hepatocytes in MPCCs are capable of producing infectious
virions, filtered culture supernatants were used to inoculate naYve Huh-7.5 cells, followed by
staining for HCV nonstructural protein 5A (NS5A) at 72 h post-infection. Infectious virus was
detected in MPCC supernatants harvested at day 4 post-infection and for all time points
measured up to day 12 (Figure 3-7). Supernatants from MPCCs infected in the presence of
specific antiviral inhibitors did not yield NS5A-positive foci in Huh-7.5 cells, indicating that de
novo virus production, rather than carry-over of the inoculum, was detected. Attempts to passage
MPCC-produced virus onto nafve MPCCs were unsuccessful, likely due to the low titers
produced by the primary cells which also precluded further biophysical analysis of the virus.
3.2.4. Proof-of-principle for preclinical screening of anti-HCV therapeutics in MPCCs
Persistently infected MPCCs may be a viable and relevant platform for preclinical screening of
anti-HCV therapeutics. Antibodies blocking HCV entry factors, in particular CD81 and
SCARB1, have proven effective in vitro [48, 209, 210] and in small animal models [210]. We
tested the ability of monoclonal antibodies against these cellular targets, as well as four
antibodies specific for HCV E2, to inhibit HCVcc entry in MPCCs; none of these reagents had
previously been tested in primary cell cultures. Anti-CD81 (JS-81) blocked HCVcc entry very
efficiently (IC 50 < 1 ptg/mL), whereas anti-SCARB 1 (C 167) did not efficiently block uptake.
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Figure 3-7. Primary human hepatocytes in MPCCs produce infectious virus. (a)
HCVcc infection kinetics in primary hepatocyte MPCCs. Primary hepatocytes in MPCCs
were infected with JcFLAG2(p7-nsGluc2A) (circles) or mock infected (triangles). After
24 h, virus was removed and MPCC medium added; samples were taken daily and media
replaced with washing three times every 48 h. (b) Schematic of the experimental setup.
Supernatants collected pre- and post-wash at days 4, 6, 8, 10, and 12 following infection
were used to infect naive Huh-7.5 cells. 24 h post-infection, media were replaced and
nonstructural protein 5A (NS5A) staining was performed 72 h post-infection to visualize
HCV infection. (c) HCV infection of Huh-7.5 cells was visualized by
immunocytochemical staining for NS5A. Days indicate the time points when
supernatants were taken from the infected MPCC cultures.
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All antibodies against E2 were able to inhibit HCVcc infection, although with varying
efficiencies (IC5 0 for AP33 > 3/11 > CBH5 > AR3A) (Figure 3-8A). A variety of specific
antivirals targeting HCV enzymes are also under preclinical development. Unfortunately, in vitro
models capable of simultaneously assessing drug toxicity and efficacy are not widely available.
We have previously shown the utility of MPCCs in drug metabolism and toxicity screening via
assessment of gene expression profiles, phase I/II metabolism, canalicular transport, secretion of
liver-specific products, and susceptibility to hepatotoxins [150]. Here, we examined the use of
MPCCs in evaluating antiviral efficacy (Figure 3-8B). We measured HCV replication by
luciferase activity at 4 days post-treatment with protease inhibitors (BILN2061 and ITMN191),
polymerase inhibitor (2'CMA), or IFN-a. These compounds inhibited HCV replication in the
sub-micromolar range, indicating the relevance of MPCCs for monitoring HCV inhibition. We
then evaluated the efficacy of protease inhibitors (SCH-6 and BILN2061) and polymerase
inhibitor (2'CMA) in HCVcc-infected MPCCs pretreated for 3 days with compounds known to
modulate drug metabolism and other cellular functions in vivo (Figure 3-8C) [150]. We found
that the addition of certain drugs severely reduced the efficacy of SCH-6 and 2'CMA, as
compared to DMSO solvent control. Although the mechanisms underlying these adverse drug
interactions remain unknown, these observations demonstrate the importance of conducting drug
combination studies during in vitro efficacy assessment. These studies indicate that MPCCs may
be well-suited as a metabolically competent in vitro model of the liver, allowing HCV replication
to be studied over several days to weeks, and a variety of intervention strategies to be tested for
both efficacy and toxicity.
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Figure 3-8. Utility of primary human hepatocyte MPCCs in antibody and small
molecule screening. (A) Dose-dependent inhibition of HCVcc replication in MPCCs
treated with antibodies against HCV glycoproteins (AP33, 3/11, CBH5, AR3A) or
cellular CD81 (JS-81). Antibody concentrations are 0.1 (light gray), 1 (dark gray), and 10
(black) pg/mL (B) Dose-dependent inhibition of HCVcc replication in MPCCs treated
with IFN-a (up to 0.13 pM) or small molecules (NS3-4A protease inhibitors, BILN2061
and ITMN191, or polymerase inhibitor, 2'CMA). HCVcc-infected MPCCs were pulse-
treated for 2 days with compounds and supernatants were collected at days 2 and 4
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(shown) post inhibitor treatment. (C) Drug-drug interactions lead to reduced efficacy of
small molecules in HCVcc-infected MPCCs. Infected MPCCs were treated for 3 days
with prototypical inducers of drug metabolism enzymes [150, 211], followed by
treatment of cultures with small molecules for 2 days. In all experiments, HCVcc
replication was monitored by luciferase secretion into the supernatants. Mean and
standard error of the mean are shown.
3.2.5. Discussion on MPCCs as an in vitro model of infection and test-bed for antivirals
Here we have described a microscale primary human hepatocyte in vitro culture platform that
supports the entire HCV life cycle. Primary hepatocyte MPCCs are stable for several weeks and
therefore allow monitoring of human hepatotropic infections over extended periods of time.
Although this is an important step forward, limitations remain. Entry of HCVpp and tissue
culture-derived virus into MPCC hepatocytes was inefficient. Although the four critical viral
entry factors are present on these cells, it is possible that differences in their spatial distribution
might account for the low uptake efficiency. Indeed, antibodies block entry into primary
hepatocytes at different efficacies than previously reported [212-214], possibly due to limited
accessibility of the HCV entry factors on polarized cells. Furthermore, following isolation from
the liver and disruption of hepatic polarity, it may be that viral entry factors on the membranes of
some MPCC hepatocytes do not reach the threshold quantity and appropriate polarized
distribution required for efficient viral uptake. We also did not observe any increase in the
number of infected cells over time, arguing for limited spread of HCV in the cultures. Several
factors could contribute to this phenomenon, including limited numbers of infectious particles,
heterogeneous polarity, or an inherent or acquired refractory nature of a proportion of cells.
Furthermore, certain critical host factors may be heterogeneously expressed and therefore
limiting in some cells, rendering them resistant to infection or unable to sustain HCV RNA
replication. Although our data demonstrate that primary hepatocytes in MPCCs can produce
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infectious virus, the titers are low and few infectious virions are available for spread. The low
permissiveness of MPCC hepatocytes to HCV may also reflect the in vivo reality of chronic
hepatitis. Technical challenges have traditionally made it difficult to estimate the number of
infected cells in an HCV-positive liver. Recently, however, two-photon microscopy methods
have been used to suggest that only a small proportion (7-20%) of patient hepatocytes express
viral antigens [215]. Although further improvements in infection efficiency may be possible, our
system lays the foundation for preclinical assessment of antiviral therapeutics against human
hepatotropic pathogens in a more physiologically relevant microenvironment. Importantly, due
to the phenotypic stability of MPCCs, infection processes can be monitored longitudinally,
potentially allowing the kinetics of viral spread and antiviral signaling to be characterized at the
single cell level. The polarized nature of the MPCC hepatocytes allows HCV entry and uptake
inhibitors to be studied in the context of intact tight junction structures. Furthermore, using sera
from HCV-infected patients and a very sensitive fluorescent reporter system [192], we were able
to detect an extremely low frequency of productive infection, suggesting that a combination of
authentic virus and host cells may be achievable. Proof-of-principle studies reported here also
demonstrate the value of MPCCs in drug studies. The high baseline activities of drug metabolism
enzymes (i.e., cytochrome P450s) and their drug-mediated induction/inhibition in MPCCs [150]
allows for simultaneous measurements of drug efficacy, drug-drug interactions, and drug
toxicity, thereby providing critical preclinical parameters. These advantages combine to make
MPCCs a highly valuable system for studies of HCV biology.
Although low quantities of antigen and HCV RNA in hepatocytes are apparently consistent with
in vivo pathophysiology, it is still surprising that infection in MPCC hepatocytes is cleared
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acutely over two weeks. This is in stark contrast to the standard hepatoma models of infection
used by HCV reporters in which infection is robust, progressive, and persistent, with an
appreciably greater portion of cells infected. One hypothesis to explain these differences is that
primary hepatocytes with intact innate immune signaling are capable of mounting an interferon
response characterized by expression of interferon-stimulated genes (ISGs) that curtails viral
spread and persistence [216-218].
3.2.6. Interferon signaling clears HCV infection acutely in primary adult hepatocytes
To determine whether interferon signaling constrains infection, we inhibited interferon signaling
using three exogenous agents that disrupt various parts of the signaling cascade: a Janus-
associated kinase (JAK) inhibitor (JAKi) that is a pyridone-containing tetracycle targeting JAK 1,
JAK2, JAK3, and tyrosine kinase 2 (Tyk2) [219]; the lentivirally introduced parainfluenza virus
5 V protein (PIV5V) that binds and inhibits melanoma differentiation-associated gene 5 (MDA5)
as well as induces proteosomal degradation of signal transducer and activator of transcription 1
(STAT1) [220, 221]; and BX795, an aminopyrimidine-containing inhibitor of tank-binding
kinase 1 (TBK1) and IxB kinase E (IKKc) [222-224]. While luminescent signal from Gluc-
expressing HCV dissipates over two weeks post infection (Figure 3-9A), inclusion of JAKi,
PIV5V, or BX795 lead to a significant increase in luciferase signal by Gluc-expressing HCV as
well as qualitative persistence presumably characteristic of infection in vivo (Figure 3-9A,
Figure 3-10). Further, infection frequency of hepatocytes was determined using a fluorescent
reporter of HCV nonstructural protein 3/4A (NS3/4A) activity [57]. Suggesting successful viral
spread, more NS3/4A+ hepatocytes were detected upon introduction of interferon pathway-
interrupting agents (Figure 3-9B); NS3/4A+ cells demonstrate a focal pattern (Figure 3-11)
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Figure 3-9. Inhibition of interferon (IFN)-signaling rescues hepatitis C virus (HCV)
infection. (A) JAK inhibitor (JAKi) was dosed (1 pM) starting one day pre-infection and
continuously thereafter. Parainfluenza virus 5 V protein (PIV5 V) was lentivirally
introduced 3 days pre-infection to give time for expression. BX-795 inhibitor of TBK1
and IKKc was dosed (1 piM) starting one day pre-infection and continuously thereafter.
Relative light units (RLU) from Gluc-expressing HCV presented on a logarithmic scale
versus days post infection (DPI). Difference between any intervention and control (CTL)
was highly significant at all time-points by ANOVA. (B) NS3/4A reporter [57]
translocations per MPCC island shown 7 dpi (approximately 200 heps/island) (n > 75 per
condition). Difference between any intervention and CTL significant by ANOVA. (C)
Viral titer (TCID50/mL) presented on a log scale for 7 dpi as determined by passaging
onto naive Huh-7.5s. Difference between any intervention and CTL significant by
ANOVA. Data in (A)-(C) are presented as p ± (T.
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Figure 3-10. Linear range of dose response of JAK inhibitor (JAKi) and BX-795.
Compounds were dosed starting one day pre-infection and continuously dosed thereafter.
Luminescence produced by Gluc-expressing HCV shown 9 days post-infection for
various doses of compound. Linear regression performed on these data sets yielded R2
.99 for JAKi and R2 = .97 for BX-795. Data are plotted as pt ± c.
Figure 3-11. Viral spread in interferon-inhibited MPCCs. NS3/4A reporter imaging
[57] in infected, JAKi-treated MPCCs reveals large "foci" of proximal infected cells.
Representative image taken 9 dpi, focus circled in red dashed line. Scale bar = 100 ptm.
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Figure 3-12. Interferon-inhibition-mediated enhancement of infection responds to
interferon (IFN) in a mechanistically appropriate manner. Post infection, cultures
treated with JAKi, PIV5 V, and BX-795 as described were treated with IFN-p at several
doses or the polymerase inhibitor 2'CMA (2.16 pM) for 4 days before luminescence was
measured by Gluc-expressing HCV. Relative light units (RLU) presented on a
logarithmic scale as pt ± a.
[225-227]. Passaging to naive hepatoma cultures confirmed that viral titers were also elevated
with these interventions (Figure 3-10C). Finally, we performed a direct test of the role of IFN
signaling in limiting infection - delivery of IFN-p to control infected cultures cleared infection at
all doses observed, mimicking the effects of treatment with the antiviral compound 2'-C-
methyladenosine (2'CMA) that inhibits the HCV polymerase, nonstructural protein 5B (NS5B)
(Figure 3-12). Taken together, these data suggest that interferon signaling limits various steps of
the viral life cycle.
We performed several assays to study the mechanism of these interferon-disrupting agents.
Based on the described functions of these agents, JAKi should inhibit only the response to IFN;
PIV5V should inhibit both the production and response to IFN; and BX795 should only inhibit
the production of IFN. As such, treatment with JAKi or PIV5V should protect infection from the
clearing effects of IFN, but BX795 dosing should not. Consistent with this, we observed that
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though all cultures remained sensitive to 2'CMA treatment, only BX795-treated cultures
responded significantly to type I IFN (Figure 3-12). To explore the possibility that JAKi may
operate through non-STAT1 functions of JAK proteins, a screen of small molecules targeting the
alternate downstream pathways was performed; consistent with STAT1 signaling being
responsible for the rescue of infection, none of these molecules was able to enhance infection
(Figure 3-13).
To further elucidate viral clearance, we studied the expression of a panel of prototypical ISGs
early after infection. ISG upregulation is the ultimate downstream target of IFN signaling, and
ISGs are the most direct way to assess activation of an antiviral state. Consistent with detection
of HCV pathogen-associated molecular patterns (PAMPs) by pattern recognition receptors
(PRRs), infection robustly induced the expression of ISGs over mock uninfected controls
(Figure 3-14). By contrast, inhibiting IFN signaling using JAKi, PIV5 V, or BX-795
significantly reduces this ISG upregulation post-infection, accordant with IFN-mediated
elevation in ISG levels as well as ISG-mediated viral clearance (Figure 3-14). Given that HCV
has mechanisms to interrupt IFN signaling [8, 228, 229], these data raise the question of whether
the ISGs induced are in infected cells themselves or in neighboring cells; though the rapid
clearance of infection in untreated MPCCs suggests that ISGs are upregulated in initially
infected cells as well, this hypothesis could be tested using single-molecule fluorescence in situ
hybridization as described earlier in this thesis.
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Figure 3-13. Determining specificity of JAKi by testing alternative pathways
downstream of JAK signaling. (A) Numbered list of compounds (targets listed in
parentheses) for various signaling pathways downstream of JAK signaling. (B)
Numbered compounds were dosed starting one day pre-infection and continuously
thereafter at 3 doses as listed (compound 4 was tested at lower doses as listed).
Luminescence of Gluc-expressing HCV normalized by untreated infected control and
presented on a log scale as t ± o. Only JAKi elevates infection statistically significantly.
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Figure 3-14. Inhibition of interferon-stimulated gene (ISG) induction post hepatitis
C virus (HCV) infection upon inhibition of interferon signaling. Infected cultures
were lysed 48 hpi, and RT-PCR was performed and normalized by a house-keeper.
Expression of prototypical ISGs relative to infected controls is presented for interferon-
inhibiting agent treated cultures (dosed as described) as well as mock uninfected cultures.
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Collectively, these data suggest that primary adult hepatocytes mount a potent interferon
response to infection and thus intrinsically resist HCV infection, contributing to acute clearance
of infection. This contrasts significantly from the conceptual model of disease pathogenesis built
on observations in vivo and in hepatoma cell lines, where the expression of anti-interferon
machinery by HCV underlies its remarkable predilection towards chronic infection in vivo [8].
Based on these data, we hypothesized that chronicity in hepatoma cell lines may be due to
defects in innate immune signaling [41, 230]l; and that while primary adult hepatocytes are a
more physiologic host for infection, their state in vivo could be significantly different from that
in vitro. In particular, we hypothesized that liver microenvironmental signals present in vivo
could "tolerize" hepatocytes to infection by dampening the activity of interferon signaling.
The broader concept that hepatocytes are tolerized to infection has precedence [231-234].
Downstream of the enteric circulation, the liver experiences a constant influx of microbial and
other antigens which would theoretically engender a constant state of liver inflammation if
unchecked. Several other phenomena suggest the tolerogenic nature of the liver - liver allografts
experience surprisingly low immunologic rejection [235]; the "oral tolerance" effect, whereby
consumption of allergy-inducing antigens can lead to tolerance, has been partly attributed to the
liver based on loss of the effect after shunting the portal circulation across the liver [236]; and
the success of cancer metastases that invade the liver. While such tolerogenic properties are
known to be exploited by liver pathogens [232], the described mechanisms of tolerance generally
involve modulation of the activity of either innate immune effector cells or adaptive immune
cells and functions; this modulation is typically achieved by the elaboration of soluble cues by
liver nonparenchymal cells. Here, we sought to determine if such signals could also mediate
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tolerance by modulating the interferon signaling activity of the primary locus of infection itself,
the hepatocyte.
3.2.7. Screen in MPCCs identifies liver microenvironmental immunosuppressive agents
that enhance infection of primary adult hepatocytes
Based on the literature [232-234], we identified 10 candidate compounds with general
immunosuppressive qualities in the liver, some of which are already known to elicit functions by
hepatocytes - interleukin (IL)-lp, IL-4, IL-6, IL-8, IL-10, IL-13, IL-22, transforming growth
factor (TGF)-p, tumor necrosis factor (TNF)-a, and prostaglandin E2 (PGE2). We observed that
IL-4, IL-6, IL-13, and IL-22 significantly enhanced infection (Figure 3-15); IL-6 was
particularly potent, enhancing infection 10-30x across several experiments. As such, we chose to
further pursue the possible role of IL-6 in hepatocyte immunomodulation.
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Figure 3-15. Effect of liver compounds on HCV infection. MPCCs were untreated
(CTL) or dosed with compounds starting one day pre-infection (with Glue-expressing
HCV) and continuously thereafter. RLU fold over CTL is presented 7 dpi as poa.
Compounds that are significantly above CTL are presented in green (p < 0.05 as
determined by one-way ANOVA followed by Tukey post-test).
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3.2.8. IL-6 inhibits the induction of ISGs post infection via STAT3-mediated inhibition of
IFN pathway components
We next sought to determine whether the enhancement in infection by IL-6 could be explained
by an inhibition of IFN signaling. MPCCs were infected with and without exposure to IL-6, and
ISG induction was measured by RT-PCR. Like the inhibition of HCV-mediated ISG induction
using inhibitors of IFN signaling (Figure 3-14), IL-6 broadly reduced ISG induction by HCV
(Figure 3-16), suggesting that IL-6 operates through IFN pathway inhibition. To determine
possible targets of inhibition, expression of various IFN pathway components was analyzed by
RT-PCR. Consistent with the reduced ISG induction upon infection, various components of the
IFN pathway were down-regulated by IL-6 exposure (Figure 3-17); inhibition of PAMP
detection seems more significantly affected. Finally, we determined whether IL-6-mediated
enhancement of infection was dependent on the primary transcription factor activated by IL-6,
signal transducer and activator of transcription 3 (STAT3) [237]; consistent with this, the STAT3
inhibitor WP1066 [238] reduced the effect of IL-6 on infection (Figure 3-18). While subsequent
=CTL
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Figure 3-16. Inhibition of induction of interferon-stimulated genes (ISGs) post
hepatitis C virus (HCV) infection upon exposure to interleukin (IL)-6. MIPCCs were
treated with IL-6 (10 ng/mL) or untreated (CTL) starting 2 days pre-HCV infection and
continuously thereafter. Cultures were lysed 3 days post infection and RT-PCR for ISGs
(with normalization by a house-keeper) was performed. pi SEM is shown.
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Figure 3-17. Expression of key elements of the IFN cascade after exposure to IL-6.
RT-PCR was performed for various groups of the IFN pathway cascade, which
demonstrated broadly reduced levels of expression. House-keeper normalized expression
for untreated (CTL) and IL-6 (10 ng/mL) presented as expression fold over CTL, p ±o.
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Figure 3-18. IL-6 mediated enhancement of infection is dependent on signal
transducer and activator 3 (STAT3) activity. Cultures were dosed with untreated
(CTL) or treated by IL-6 (10 ng/mL) starting 2 days pre-infection (by Gluc-expressing
HCV), and by carrier control DMSO or by STAT3 inhibitor WP1066 (10 pM) starting 1
day pre-infection and continuously thereafter. Data presented as IL-6 RLU fold over
untreated CTL, pt ± SEM. Two-sided t test confirmed significance (* p < 0.05).
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investigation will be necessary to fully elucidate the mechanism of infection rescue, these data
implicate depression of IFN pathway activity.
3.2.9. Innate immune inhibition enhances the growth of non-JFH-1 strains of HCV
As described earlier in this thesis, a significant problem in the study of HCV is the general
inability to cultivate non-JFH-1 strains of HCV [32]. We sought to test the hypothesis that
hepatoma cells do not furnish the right environment for the growth of these HCV strains due to
aberrations in host factor expression and function, and that primary hepatocytes may be a more
appropriate environment for their cultivation. Because curated virions cannot be sourced due to
the lack of a culture model, we used synthesized versions of the Con1 (genotype 1b) RNA with
an embedded Gluc gene. We optimized the transfection of MPCCs using novel "lipidoids"
materials which demonstrate successful siRNA delivery in primary hepatocytes in vivo [239].
After showing that these materials can deliver JFH-1 genomes to recreate robust infection (data
not shown), we transfected Gluc-expressing Conl into MPCCs. We observed that although
MPCCs did not sustain infection in the absence of innate immune inhibition, there was a
significant increase in infection after IFN inhibition using either PIV5 V or IL-6 (Figure 3-19).
While we do not observe robust infection of Con1, disproving the notion that the use of primary
hepatocytes is sufficient for robust growth, these data are consistent with an innate immune
barrier to growth of HCV Conl as well.
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Figure 3-19. Infection by Con1 HCV in MPCCs is increased by innate immune
inhibition. (A) Gluc-expressing Con1 RNA was transfected using lipidoids into CTL
(DMSO) cultures, PIV5 V transduced cultures, and IL-6 (10 ng/mL) treated cultures.
PIV5 V and IL-6 demonstrated significantly higher infection (p < 0.05 by one way
ANOVA followed by Tukey post-test). Data presented as ji±a. (B) NS3/4A infection
frequency reporter [192] demonstrated sparse positive events only in immunosuppressed
cultures.
3.2.10. Innate immune inhibition enhances the growth of liver-stage malaria
Our lab has recently demonstrated the MPCCs can be used to study liver-stage malaria [240].
Here, we sought to determine whether innate immune interferon signaling presents a barrier to
infection by malaria as well. We observed that P. falciparum infection was significantly
enhanced by the inhibition of IFN signaling using JAKi, as measured by both quantity (Figure
3-20A) and size (maturity) (Figure 3-20B) of exoerythrocytic forms (EEFs). RT-PCR verified
that the expression of ISGs after P. berghei infection was reduced in the presence of JAKi or IL-
6 (Figure 3-20C). Notably, while JAKi did not inhibition IFN expression as expected
mechanistically, IL-6 inhibited IFN expression as well as ISGs, consistent with IL-6 interfering
with pathogen detection by PRRs (Figure 3-20C). Collectively, these data suggest that innate
immunity mounts a significant barrier to hepatotropic infections broadly; tolerization of
hepatocytes in the liver could thus contribute to the success of these infections in vivo.
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Figure 3-20. Liver-stage malaria infection in MPCCs is increased by innate immune
inhibition. (A) Exoerythrocytic forms (EEFs) of P. falciparum were quantified in CTL
(DMSO) treated cultures and JAKi treated cultures. Difference was statistically
significant as verified by t test. (B) EEFs of P. falciparum were larger in the presence of
JAKi treatment. (C) RT-PCR was used to measure IFN and ISG levels post-infection (by
P. berghei) in the presence of CTL, JAKi, or IL-6 treated cultures. House-keeper-
normalized expression is presented relative to CTL expression as p a.
3.2.11. Discussion on interferon control of infection by the liver
As described, the development of MPCCs enabled us to study HCV infection in a more
physiologic, primary hepatocyte host. Using this model, we made the unexpected finding that
primary adult hepatocytes acutely clear infection, in contrast to hepatoma cells. We hypothesized
that intact innate immune signaling could explain this, and indeed demonstrated this using
exogenous inhibitors if IFN signaling which profoundly enhanced viral infection signal and
persistence. This observation raises an important question - how does HCV achieve robust
infection and chronicity in the presence of intact IFN signaling? Based on the general notion that
74
JA K
Ki
the liver is immune-tolerant from an adaptive and innate immune effector cell perspective, we
sought to determine whether endogenous signals present in the liver microenvironment could
enhance infection in hepatocytes by tolerizing hepatocyte-intrinsic innate immune signaling. A
screen of normally expressed liver cytokines with immunosuppressive qualities as described in
the context of immune effector cells revealed hits that significantly boosted infection. In
particular, IL-6 enhanced infection 10-30x. We showed that IL-6 does indeed minimize the
activation of ISGs concomitant with infection, likely by inhibiting sensing and the response to
infection. IL-6 is normally elaborated at a basal level by liver-resident Kupffer cells in response
to microbial antigens such as lipopolysaccharide (LPS) entering the liver from the portal
circulation [241]. As such, we propose a new working model for another facet of liver
tolerization that may operate in parallel with other tolerizing features of the liver [232]. LPS-
stimulated Kupffer-cells secrete IL-6 which, itself and likely in conjunction with other liver
cytokines, inhibits IFN signaling; this in turn induces tolerization to inflammatory substances
and infection in liver hepatocytes that is exploited by hepatotropic pathogens (Figure 3-21).
Experiments in more complex cellular in vitro models (e.g. including Kupffer cells) and in vivo,
as well as generalization to other hepatotropic pathogens, will be essential for validating and
understanding the broader impacts of this conceptual model. Excitingly, inhibiting IL-6 signaling
could restore IFN activity and thus be an attractive approach to therapy of hepatotropic
pathogens; this is particularly promising since neutralization of IL-6 signaling is already used
clinically for other indications [242]. Lastly, from a model development perspective, inhibition
of IFN signaling in MPCCs through either exogenous or endogenous agents will enable the study
of persistent infection in vitro, enhancing our ability to dissect host-virus interactions and to
study phenomena of robust infection such as viral spread.
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Figure 3-21. Model. Microbial antigens from the gut induce Kupffer cells to produce
immunoregulators including interleukin-6 (IL-6) which tolerizes hepatocytes
immunologically to inflammatory substances. This dampened surveillance is in turn
exploited by pathogens such as hepatitis C virus (HCV), which can mount robust
infection as a result.
3.2.11. Personal contributions to this work
This work was divided into two projects - development of the primary hepatocyte model of
infection [201], and use of the model to study innate immune signaling. For the first project, the
author of this thesis worked in a team lead by Drs. Alexander Ploss and Salman Khetani to assist
in experimentation, as well as re-validate, characterize, and explain findings made by others. For
the second project, the author of this thesis lead a group of researchers in planning, performing,
and interpreting experiments.
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3.3 Materials and methods
Virus genomes and stocks
JclFLAG2(p7-nsGluc2A) is a fully-infectious HCVcc reporter virus encoding Gaussia luciferase between p7 and
NS2 [207]. Virus stocks were created by electroporation and titered by limiting dilution as previously described
[48].
Liver sections and hepatocytes
Primary human hepatocytes were purchased from vendors permitted to sell products derived from human organs
procured in the United States by federally designated Organ Procurement Organizations. Vendors included: Celsis
In vitro Technologies, BD-Gentest and CellzDirect. Human hepatocytes were pelleted by centrifugation at 50-100
xg for 5-10 min at 4 'C, resuspended in hepatocyte culture medium, and assessed for viability using Trypan blue
exclusion (typically 70-90%). Liver-derived nonparenchymal cells, as judged by size (<10 jim diameter) and
morphology (nonpolygonal), were consistently found to be less than 1% in these preparations. Human liver sections
were obtained from the New York Presbyterian Hospital from uninfected donor tissue deemed unacceptable for liver
transplantation. Tissue was processed by immediately freezing in OCT compound at -80'C or by fixation in 10%
formalin solution for 24 h followed by paraffin embedding. Tissue sections were cut (-5-6 jim) on poly- L-lysine
coated slides. Human serum and plasma samples were obtained at Weill Cornell Medical Center. All protocols for
human primary material procurement were approved by the Committee on Use of Human Experimental Subjects,
MIT, or by the IRB, Rockefeller University and Weill Cornell Medical Center.
Micropatterned co-cultures of primary human hepatocyte sand supportive stromal cells
Off-the-shelf tissue culture polystyrene (24- and 96-) or glass bottom (24-) multi-well plates, coated homogenously
with rat tail type I collagen (25-50 jig/ml), were subjected to soft-lithographic techniques [150] to pattern the
collagen into micro-domains (islands of 500 jim in diameter with 1200 im center-to-center spacing). To create
MPCCs, hepatocytes were seeded on collagen-patterned plates that mediate selective cell adhesion. The cells were
washed with medium 2-3 h later (-3x104 adherent hepatocytes in 96 collagen-coated islands in 24-well plate and
-4.5x103 hepatocytes in 14 islands in 96-well plate) and incubated in hepatocyte medium overnight. Hepatocyte
culture medium was DMEM with high glucose, 10% FBS, 0.5 U/ml insulin, 7 ng/ml glucagon, 7.5 jig/ml
hydrocortisone and 1% penicillin streptomycin. 3T3-J2 murine embryonic fibroblasts were seeded (9x 104 cells in
each well of 24-well plate and 1.4x 104 cells in each well of 96- well plate) in fibroblast medium (DMEM with high
glucose, 10% bovine serum and 1% penicillin-streptomycin) 12-24 h later. Fibroblast to-hepatocyte ratio was
estimated to be 4:1, once the fibroblasts reached confluency. Fibroblast culture medium was replaced with
hepatocyte culture medium 24 h after fibroblast seeding and subsequently replaced daily. Control conventionally-
plated pure hepatocyte cultures (Collagen gel sandwich, Matrigel overlay, Matrigel substratum, and randomly
distributed Cocultures of hepatocytes and murine fibroblasts) were created as described previously [150].
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Pseudoparticle generation and infection assays
Pseudoparticles were generated by cotransfection of plasmids encoding an EGFP-encoding provirus (CSGW) or
provirus encoding transgene (pTRIP), HIV gag-pol, and envelope glycoprotein(s), as previously described [204].
HCVpp were generated using H77 EI/E2 (residues 170-746).
Antibodies, immunostaining, and blocking
For immunostaining, cells or tissue sections were fixed in 1% paraformaldehyde and/or -20 'C methanol. Following
washing and blocking in 1% BSA/0.2% milk or 1% BSA/0.3% Triton X-100 in PBS, cells were incubated in
primary antibody overnight at 4 'C: mouse anti-human CD81 (clone JS-81, BD Pharmingen; 1:200), rabbit anti-
SCARBI (NB 110-57591, Novus Biologicals; 1:100), rabbit anti-CLDN1 (51- 9000, Zymed; 1:200), rabbit anti-ZO1
(61-7300, Zymed; 1:200), mouse anti- OCLN (33-1500, Zymed; 1:200), mouse anti-MRP2 (Clone M2III-6, Kamiya
Biomedical; 1:50), mouse anti-EEAl (clone 14, BD Biosciences; 1:100), mouse anti-NS5A (9E10 [48], 1:2000).
Secondary antibodies were goat-anti-mouse or goat-anti-rabbit AlexaFluor488- or AlexaFluor594-conjugates
(Invitrogen; 1:1000) for immunofluorescence, or goat-anti-mouse HRP (ImmPress kit, Vector Labs) with DAB+
substrate (Dako) for immunohistochemistry. Nuclei were detected using Hoechst dye (500 ng/mL in PBS,
Invitrogen). Images were captured on a Nikon inverted microscope using SPOT image analysis software. Confocal
images were captured on a Zeiss LSM 510 inverted microscope at 0.3 pim optical slices using Zeiss software (v3.2).
Z-stack files were uploaded into ImageJ64 software with images generated using a "Sum Slices" projection and 3D
renderings were done using Imaris software. Final images were assembled using Adobe Photoshop CS3 software.
Blocking experiments used human anti-SCARBl antibody C167 [209], anti-CD81 (clone JS-81; BD Pharmingen),
anti-E2 3/11 [243], and antibodies kindly provided by A.H. Patel (University of Glasgow, Scotland) (AP33) [212],
S.K. Foung (Stanford University, Palo Alto, CA) (CBH5) [213], and D.R. Burton (The Scripps Research Institute,
La Jolla, CA) (AR3A) [214]. Human IgGI (clone MOPC-21), IgG4 (MOR6391), and rat IgG2a (MCA1124R)
isotype control antibodies were purchased from AbD Serotec.
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Chapter 4. Illuminating intercellular heterogeneity of viral infection
4.1 Introduction
The heterogeneity amongst single cells in a population has long been appreciated in numerous
prokaryotic and eukaryotic cell systems [244]. The advent of quantitative imaging technologies
for ascertaining cell-cell variability in molecular composition has revolutionized our
understanding of single-cell heterogeneity [158-162], demonstrating how biochemical variations
underlie decision-making in diverse processes such as migration, nutrition, and differentiation.
Single-molecule RNA imaging in particular has been applied to assessing inter-cell differences
in mRNA expression, uncovering extensive gene expression heterogeneity that contributes to
phenotypic variation [163-165, 167-172, 245]. One unexplored area for which quantitative,
single-molecule RNA imaging has similar potential is in elucidating the single-cell heterogeneity
of RNA virus infection. RNA viruses must enter and replicate within individual host cells, and at
any time, cells presumably contain different quantities of genomic viral RNA (vRNA) species.
While much of this asynchrony likely stems from the stochastic nature of infection, inter-cell
variations in host gene expression also underlie such differences [162, 246]; conversely,
heterogeneous infection likely engenders single-cell differences in host gene expression as well.
Although mastery of the systems biology of RNA virus infection will require a window into this
rich single-cell complexity, such information is typically lost with the use of conventional,
population assays for infection and for host gene expression.
Single-molecule RNA fluorescence in situ hybridization (smFISH) methods have been
developed that allow imaging of individual mRNA molecules [164, 168], advancing our
appreciation of cellular heterogeneity. smFISH is highly specific and sensitive, enabling
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quantification of cell-cell differences; can be performed in numerous cell culture models and
tissues without genetically modifying target RNAs or host cells; is amenable to multiplexing
several RNA species; is compatible with immunocytochemistry; and is experimentally facile,
involving readily available reagents, straightforward protocols, and standard epifluorescence
microscopy [173].
Despite significant advances in vRNA imaging [247, 248], to our knowledge very few reports
suggest single viral genome imaging [249, 250]; though these studies are of great potential value
to investigations of genome trafficking and co-localization with host or viral factors, it is unclear
whether the specificity, sensitivity, and resolution of these assays are sufficient to quantify
individual viral genomes at the single-cell level. To determine if smFISH permits such imaging,
we applied it to hepatitis C virus (HCV). HCV chronically infects the liver hepatocytes of almost
200 million worldwide and is a major cause of end-stage liver disease [2]. HCV drug
development has been challenged by the lack of sensitive and quantitative tools for studying
infection. It is a single-stranded, positive-sense RNA virus, in that the "positive" (or sense)
strands contained in HCV virions replicate through intermediate "negative" (or antisense) strands
[11]. Here, we show that smFISH affords specific and sensitive, quantitative detection of
individual positive and negative strands of vRNA as diffraction-limited spots. We demonstrate
that single-cell multiplexing of positive and negative vRNA strands illuminates the dynamics of
positive and negative strand proliferation and can thus enhance our understanding of the viral life
cycle. We also apply smFISH to multiplex vRNA with host gene expression and shed light on
host-virus interactions, by revealing that the infection load of individual cells correlates with
their response to an innate immune cytokine.
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4.2 Results and discussion
4.2.1. Specific and sensitive, single-molecule imaging of genomic vRNA
In mRNA smFISH (Figure 4-1A) [168], cells are fixed and permeabilized, and fluorophore-
labeled probe sets targeting the mRNA of interest are delivered. After hybridization, the
aggregate fluorescence intensity at the site of individual mRNA molecules is sufficient to
visualize them as diffraction-limited spots using standard epifluorescence microscopy; Z-stacks
can be performed to acquire all such spots in the target cells. smFISH is highly sensitive and
specific; further, comparison with real-time polymerase chain reaction (RT-PCR) corroborates
mRNA transcript enumeration by smFISH spot counting, furnishing a quantitative assay for cell-
cell differences in mRNA transcript levels.
We adapted this smFISH method to visualize genomic vRNA by studying HCV infection of the
Huh-7.5 hepatoma cell line [51, 251], and to determine whether the assay can be used
specifically and sensitively in this setting. We developed two probe sets each for both the HCV
positive and negative strands - a Cy5 probe set targeting the 5' half of the strand, and an
Alexa594 probe set targeting the 3' half. While smFISH performed on uninfected hepatoma
cultures (Figure 4-2A) or infected cultures in the absence of probe sets (Figure 4-2B) revealed
no spots, infected cultures imaged simultaneously with both Cy5 and Alexa594 probe sets for the
positive or negative strand revealed diffraction-limited spots in both channels (Figure 4-1B).
The high co-localization frequency of these spots (>80%) (Figure 4-1B) supports imaging
specificity and that only one probe set is required to image each strand; further, this frequency is
quantitatively similar to what has been observed for mRNAs [168]. Occasional non-co-localizing
spots may reflect incomplete vRNA or vRNA with regions of poor accessibility to FISH probes.
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Figure 4-1. Specific and sensitive imaging of individual molecules of genomic viral
RNA (vRNA). (A) Schematic illustration of single-molecule RNA FISH (smFISH)
method [168]. A set of 48 DNA FISH probes (20 nucleotides/probe) that are each end-
labeled with one fluorophore targeting non-overlapping portions of the target RNA (Left)
are introduced to fixed and permeabilized target cells. Hybridization of probes to the
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target RNA (Center) produces sufficient local fluorescence for the RNA molecule to be
visualized as a diffraction-limited spot using standard epifluorescence microscopy
(Right). As shown previously, spots are detected only once a minimum number of probes
bind the target, reducing false positives due to random, off-target probe binding. Z-stacks
can be performed to acquire all such spots in target cells. Using custom software, spots
can be identified in three dimensions and quantified over a wide dynamic range, ranging
two orders of magnitude from zero to several hundred spots per cell; alternatively, for
cells with too many spots to identify individually, an estimate can be obtained by
integrating the fluorescence intensity in the cell. Comparison with real-time polymerase
chain reaction (RT-PCR) corroborates transcript enumeration by smFISH spot counting,
showing that smFISH is quantitative. (B) Co-localization of diffraction-limited spots in
infected Huh-7.5 hepatoma cultures (16 hours post infection) was determined by
simultaneously introducing two spectrally distinct probe sets (coupled to Cy5 and
Alexa594 respectively) targeting different portions of the same genomic vRNA strand.
Typical images of positive (Left, Z-stack projection, scale bar ~ 5.0 ptm; Inset, -2x
zoom) and negative (Center, Z-stack projection, scale bar ~ 4.0 tm; Inset, -2x zoom)
strands shown. Percentage of Cy5 and Alexa594 spots that co-localize with the other
channel shown for both strands (Right). (C) Histogram representation of integrated
intensity distribution for spots 24 hours post infection (hpi) for both strands. (D) Number
of positive strands in individual cells at 12 and 24 hpi (means in red). Difference was
statistically significant: ****p < 0.0001 (two-tailed t test). (E) Number of positive strands
in individual cells in DMSO or the HCV NS5B polymerase inhibitor 2'CMA at 24 hpi
(means in red). Difference was statistically significant: ****p < 0.0001 (two-tailed t test).
(F) NS3/4A activity reporter [57] deems cells infected based on nuclear fluorescence and
uninfected based on cytosolic fluorescence. The Huh-7.5 Clone 8 line which carries this
reporter stably was used to compare NS3/4A imaging with smFISH. Sample images from
the same field of view for both NS3/4A reporter (Left, scale bar ~ 18.5 pim) and smFISH
(Center, ~ 18.5 pim) are shown. Number of positive strands in NS3/4A- or NS3/4A+ cells
24 hpi are provided (Right). Stat. significant diff: ****p < 0.000 1 (two-tailed t test).
We next determined whether vRNA smFISH spots were indicative of single genomic strands or
higher-order aggregates of RNA by integrating the total spot fluorescence for many spots. The
spot intensity distribution was unimodal (Figure 4-1C), suggesting that spots represent single-
molecule events [252]. Infrequent higher-order spots are detected, and may represent clusters of
proximal genomes, accordant with many viruses employing organelle-like replication complexes
[253-255].
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Figure 4-2. Specific and sensitive imaging of viral RNA in hepatoma and primary
hepatocyte culture models. (A) Uninfected Huh-7.5 hepatoma cells imaged with probe sets for
both the positive and negative strand (Z-stack projection, scale bar ~ 4.9 pLm). (B) Infected
Huh7.5 cells imaged 24 hours post infection (hpi) on DAPI, Cy5, and Alexa594 channels but
without FISH probe sets (Z-stack projection, scale bar ~ 6.2 ptm). (C) Structured illumination
microscopy (SIM) of HCV (Cy5) and ER (Alexa594) (scale bar ~ 3.0 gm) in infected Huh-7.5
cells 24 hpi. (D) SIM of HCV (Cy5) and HCV NS5A (Alexa594) (scale bar ~ 3.7 pm) in
infected Huh-7.5 cells 48 hpi. (E) Primary induced pluripotent stem-cell (iPSC)-derived
hepatocyte-like cells imaged 1 week post infection [181] using confocal microscopy (scale bar
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~ 4.7 pm). Alexa594 (green) imaging performed without probe sets as a control to aid in the
identification of frequent lipid-like autofluorescent foci (green arrows) distinct from diffraction-
limited spots specific to the delivered probe set. (F) Primary human fetal liver cells (HFLCs)
imaged 48 hpi by the J6/JFH Clone 2 strain of HCV (Z-stack projection, scale bar ~ 4.2 pim).
Alexa594 (green) imaging performed without probe sets also to identify occasional
autofluorescent foci (none in this field of view). (G) Number of positive strands in individual
HFLCs in DMSO or the HCV NS5B polymerase inhibitor 2'CMA at 48 hpi (means in red).
Difference was statistically significant: ****p < 0.0001 (two-tailed t test). (H) Fraction of
HFLCs "infected" at 48 hpi depending on the minimum threshold number of genomes for a cell
to be deemed infected. NS3/4A activity reporter [57] infection rate estimate on replicate
samples provided as a comparison.
Consistent with smFISH specificity and with spots serving as a measure of infection, the number
of spots increases with time post infection (Figure 4-1D), and the number of spots is greatly
reduced by the inclusion of an antiviral compound, the HCV non-structural protein 5B (NS5B)
polymerase inhibitor 2'-C-methyladenosine (2'CMA) (Figure 4-lError! Reference source not
found.E). We also compared vRNA smFISH to a highly sensitive, single-cell fluorescent
reporter of HCV infection that discriminates infected from uninfected cells based on HCV non-
structural protein 3/4A (NS3/4A) protease activity [57]. In this assay, cytosolic fluorescence is
observed in the absence of NS3/4A activity (NS3/4A-), whereas nuclear florescence is induced
in cells with active NS3/4A (NS3/4A+). Notably, this method has proven more sensitive than
viral antigen immunostaining (data not shown), paralleling the general assumption that
enzymatic activity is inherently amplified and thus a highly sensitive indicator of enzyme
presence. We observed that smFISH spots are significantly more numerous in NS3/4A+ than
NS3/4A- cells (Figure 4-1F), verifying that smFISH qualitatively measures functional infection.
Notably, even NS3/4A- cells display a wide range of smFISH spot counts, suggesting that vRNA
smFISH is sufficiently sensitive to detect infection ahead of an enzymatic reporter, and that
vRNA imaging in general is more sensitive than viral protein imaging.
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In addition to being specific and sensitive, smFISH maintains spatial information and can be
combined with staining for other targets, permitting localization of vRNA with respect to
intracellular components. As a proof-of-principle, we performed smFISH using three-
dimensional structured illumination microscopy (3D-SIM) [256], which enables fluorescence
imaging at sub-diffraction-limit resolution. 3D-SIM reveals HCV positive strands positioned
along the endoplasmic reticulum (ER) (Figure 4-2C), which may reflect strand replication along
ER-derived membranes [257]; further, imaging can be performed alongside immunostaining for
the HCV non-structural protein 5A (NS5A) (Figure 4-2D). As such, smFISH could assist
investigations of vRNA trafficking and association with host or viral factors.
While hepatoma cells as used above have been central to the study of HCV, they have numerous
drawbacks including abnormal proliferation, gene expression, innate immune signaling, and
polarization [37-42]. Thus, there is interest in studying HCV infection in primary hepatocytes,
but infection assays have generally been insufficiently sensitive given the high autofluorescence
and low levels of HCV antigens [215, 258]. To determine if sensitive detection of single vRNA
strands can overcome these difficulties, we performed smFISH on two primary hepatocyte
models of HCV infection - induced pluripotent stem cell (iPS)-derived hepatocyte-like cells
(iHLCs) [181] and primary human fetal liver cells (HFLCs) [259]. Infected iHLCs (Figure 4-2E)
and HFLCs (Figure 4-2F) demonstrate positive strand vRNA smFISH spots, with fewer strands
detected in the presence of 2'CMA (Figure 4-2G). While only 40% of HFLCs were NS3/4A+
using the above-described enzymatic reporter in replicate samples, smFISH spots were detected
in most cells (Figure 4-2H); indeed, 93% of HFLCs had at least one viral genome. The
phenotypic implications of containing viral genomes must thus be understood to define
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"infection" at the cellular level, particularly in the setting of intact innate immune signaling
where certain cells may successfully control attempts at infection. The ability to detect HCV
infection in primary cultures suggests that smFISH will assist in studies ideally performed in
primary cultures, including investigations of host-innate immune interactions, the role of
hepatocyte polarization in infection, and the focal spreading of infection via cell-to-cell
transmission [215, 225, 226]. As smFISH has been performed in tissue samples as well [260],
such findings could be extended to in vivo studies as well.
4.2.2. Corroboration of smFISH genome quantification using a novel bulk infection assay
As shown, vRNA smFISH enables specific and sensitive visualization of individual viral positive
and negative strands as diffraction-limited spots in infected cells. To determine if smFISH is
quantitative for positive and negative strands, we would ideally compare such measurements
with validated bulk assays of genomic vRNA. Unfortunately, existing PCR assays for vRNA
have not demonstrated convincing strand discrimination, with estimates of the negative/positive
strand ratio (NPSR) for HCV ranging widely from 1:10 to 1:1000 [261-272]. As such, the
negative strand has been conceptually relegated to a qualitative indicator of productive infection
in various cell types [262].
To address this shortfall and to corroborate our smFISH quantifications of both positive and
negative strands, we developed a SYBR-based, tagged quantitative RT-PCR (qPCR)-based assay
of vRNA burden in bulk populations. Total RNA is poly-A tailed, after which a tagged NV-
oligo-dT primer is used for reverse transcription off the nascent tail (Figure 4-3A); the resulting
complementary DNA (cDNA) is then used for qPCR, employing a primer for the tag sequence
87
and an HCV-specific primer for the 3' end of the target vRNA. This assay differs from previous
tagged assays in two main ways - strand specificity is introduced at the PCR stage, and
amplicons are generated that straddle the 3' ends of completed products of the viral polymerase.
Using standards for both strands individually, we confirmed that the assay is sensitive over 8
logs for both strands (Figure 4-3B). To ascertain specificity, we used cross-mixed standards to
determine that both strands could be detected unambiguously within a large range (Figure
4-3C). We next compared smFISH single-cell quantifications to bulk measurements made by
qPCR on replicate samples; both assays yielded a similar fold change in positive or negative
strand vRNA between two time-points post infection (Figure 4-3D, Figure 4-3E). Taken
collectively, these data suggest that smFISH is quantitative for both positive and negative
strands, and that these methods can help capture the elusive viral negative strand for HCV and
potentially other RNA viruses.
4.2.3. Single-cell, multiplexed quantification of viral positive and negative strands for
studying the viral life cycle
Genomic positive and negative strands are central to the fundamental processes of RNA virus
infection, including production of viral proteins, replication, and population of new virions. Our
understanding of how these functions are coordinated at the systems scale is largely based on
bulk assays of infection, which are confounded by the asynchrony and thus single-cell
heterogeneity of infection; further, strand discrimination has proven challenging even at the bulk
level, as discussed above. We applied smFISH to permit direct, simultaneous enumeration of
positive and negative strands in individual cells. Hepatoma cells were incubated in HCV and
upon transfer into fresh medium, were fixed at various hours post infection (hpi) (Figure 4-4A).
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Figure 4-3. Single-molecule RNA FISH (smFISH) is a quantitative assay as verified
by a novel bulk assay for quantifying genomic viral RNA (vRNA). (A) Schematic of
quantitative polymerase chain reaction (qPCR) assay for measuring vRNA strands.
Briefly, HCV is polyadenylated before undergoing an RT reaction with a tagged NV-
oligo-dT primer. The resulting cDNA is used for qPCR using the exogenous tag primer
and a strand-specific HCV primer directed towards the RNA 3' end. (B) Sensitivity of
method as shown by cycle threshold (Ct) as a function of strand copies. (C) Specificity of
method as shown by positive/negative strand ratio range within which single,
unambiguous PCR products were identified. (D) qPCR comparison with smFISH-based
quantification of HCV positive strands. Number of positive strands in individual cells
shown at 12 hpi and 24 hpi (means in green), with fold increase visualized by green
arrow (Left). Fold increase measured by both assays (Right). Data plotted as mean (pi)±
standard error of the mean (SEM). Difference was not statistically significant (n.s.) (p >
0.05) by two-tailed t test. (E) Assay comparison for negative strands. Number of negative
strands in individual cells shown at 12 hpi and 24 hpi (means in red), with fold increase
visualized by red arrow (Left). Fold increase measured by both assays (Right). Data
plotted as t SEM. Difference was not statistically significant (n.s.) (p > 0.05) by two-
tailed t test.
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Multiplexed imaging was performed using two spectrally distinct probe sets, each targeting a
different vRNA strand (Figure 4-4A). The resulting images at each time (Figure 4-4B) yielded a
corresponding single-cell joint distribution of positive and negative strand counts (Figure 4-4D).
Population-scale replication trends can be obtained by summarizing the strand joint distributions
with average metrics - the mean single-cell numbers of positive and negative strands, and the
mean single-cell negative/positive strand ratio (NPSR) (Figure 4-4C). Taken together, such data
portray significant inter-cell heterogeneity in strand counts at each time-point, highlighting the
asynchrony inherent in infection that is masked by bulk assays, and reveal the correlation
between positive and negative strands at single-cell level; further, they allow us to follow the
temporal evolution of infection heterogeneity.
One notable feature of these data relates to the NPSR. In contrast to the prevailing positive-sense
RNA virus dogma that positive strands are orders of magnitude more numerous than negative
strands [273, 274], the NPSR measured by smFISH in this platform is highly dynamic. We
observed that the mean single-cell NPSR starts low at 4 hpi, consistent with early virion
unpacking and minimal replication, and exceeds unity, with the negative strands outnumbering
positive strands at 12 and 24 hpi, prior to tapering thereafter (Figure 4-4C, Inset). The single-
cell strand joint distribution at 48 hpi shows that cells with fewer positive strands have greater
NPSR than those with more positive strands (Figure 4-4D, Inset); mirroring the population-scale
NPSR trends. This result is consistent with cells earlier in infection initially favoring the
production of negative strands before making further positive strands.
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Figure 4-4. Multiplexed quantification of positive and negative viral strands in
individual cells for illuminating viral replication. (A) Schematic illustration of
experiment. Huh-7.5 hepatoma cells were inoculated with HCV for 4 hours, and then
fixed for smFISH at various times thereafter (Left). Multiplexed imaging was performed
by simultaneously employing an Alexa594 probe set for the positive strand and a Cy5
probe set for the negative strand (Right). (B) Sample images at 4 (Left, Z-stack
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(C) Population-wide perspective across whole infection time-course obtained by
averaging the number of observed positive and negative strands for each cell at each
time-point (4 hpi: n = 70; 12 hpi: n = 44; 24 hpi: n = 67; 48 hpi: n = 63). Data plotted as
mean (p) ± standard deviation (a). The average single-cell negative-positive strand ratio
(NPSR) at each time-point plotted as p ± a (Inset). (D) Single-cell joint distribution of
positive and negative strands for 48 hpi presented as a scatter plot showing the strand
counts in individual cells (n = 63) (Pearson correlation coefficient p = 0.86). The dashed
line separates the regions in which positive strands are more numerous than negative
strands (below, green fill) and vice versa (above, red fill). Binning cells by positive
strands and obtaining the average single-cell NPSR for each bin is plotted as t ± a
(Inset).
Another informative facet of these data is the bimodality of the strand distribution (Figure 4-5),
with a separation of cells into subpopulations with low or high strand counts. One hypothesis to
explain this pattern is that virus entry and early infection are slow, with a relatively gradual
increase in strand counts. Upon achieving a threshold, moderate strand count, replication may
accelerate, which tracks the rapid growth of strand counts observed between 12 hpi and 24 hpi
(Figure 4-4C). Finally, single cells may saturate at some maximum number of strands,
consistent with the slower strand count growth we see from 24 hpi to 48 hpi. This saturation
could be due to the existence of a "carrying capacity" in cells wherein essential host factors are
completely saturated [275, 276], or a dynamic equilibrium where strand production is matched
by turnover of strands or dissemination of strands via new virions.
Quantitative single-cell analysis of infection heterogeneity has the potential to illuminate the
systems biology of viral replication, particularly in association with mathematical models that
could enable inference and testing of specific hypotheses given the access to such rich data [277-
284]. Such experiments will be informative with the variation of parameters such as multiplicity
of infection (MOI), and particularly enlightening in the presence of perturbations to normal
infection physiology, such as the use of mutant viral strains with uncharacterized behaviors, the
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Figure 4-5. Bimodal distribution of infection. Positive strand marginal distribution
shown as a frequency histogram at 48 hpi. Bimodality of such distributions is typically
observed, with (i) a poorly infected mode and a (ii) highly infected mode.
infection of genetically manipulated host cells, and in the presence of compounds that bind
specific viral or host targets.
4.2.4. Single-cell, multiplexed imaging of viral strands and host genes for understanding
host-virus interactions
Variability in host cell gene expression likely contributes to the heterogeneity of RNA virus
infection, and conversely, infection itself induces gene expression differences in virus-bearing
cells. Elucidating this interplay between host genes and infection is central to the study of host-
virus interactions, but correlating infection with bulk measurements of host transcript levels -
typically made by RT-PCR or transcriptional microarrays - obscures single-cell level
correlations. Ideally, single cells should be stratified two-dimensionally by grade of infection and
by host factor expression, to provide a visual map of the infection-gene expression relationship.
In principle, the use of smFISH can fill this gap, as it can quantitatively visualize cellular
mRNAs [168] and image viral genomes in a quantitative manner (Figure 4-6A). To demonstrate
this capability, we investigated how inter-cell variability in infection modulates the single-cell
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response to Type I interferon (IFN). IFN stimulation initiates JAK/STAT signaling that
culminates in the induction of antiviral interferon-stimulated genes (ISGs) [216-218], and it is
believed that HCV may interrupt this cascade [8, 228, 229]. We developed smFISH probe sets
that target mRNA transcripts for two prototypical ISGs: EIF2AK2 and ISG15. Uninfected
hepatoma cells were fixed for smFISH immediately before or after IFN-p exposure (Figure
4-6B). Imaging cells with probe sets for EIF2AK2 and JSG15 shows a baseline quantity of
diffraction-limited spots that increases significantly upon administration of IFN-p (Figure 4-7A,
Figure 4-7B, Figure 4-6D); these post-treatment ISG levels are stable from 6 to 24 h (Figure
4-7B). Notably, despite uniform IFN-P stimulation, ISG expression varies dramatically in
individual cells, mirroring the stochastic production of IFN-p in response to infection [285]; this
observed pattern raises questions as to how liver tissue coordinates an antiviral response to
infection.
Similarly, infected hepatoma cells were fixed for imaging before or after a 12 h exposure to IFN-
p (Figure 4-6B). Multiplexed smFISH was performed to obtain joint distributions of HCV
vRNA with ISG15 and with EIF2AK2. This duration of IFN-p treatment did not significantly
reduce HCV strand counts (Figure 4-7C), arguing against IFN-mediated viral clearance during
this interval. Infected hepatoma cells did not upregulate ISG mRNAs in the absence of IFN-p
(Figure 4-6D), consistent with defective innate immune signaling in Huh-7.5s [41]; further, no
correlation between ISG mRNA and HCV strands was observed (Figure 4-6D). However, after
treatment with exogenous IFN-p, ISG mRNAs were strongly correlated with HCV infection load
(Figure 4-6C, Figure 4-6D). ISG levels in poorly infected cells were similar to those in
uninfected controls, consistent with minimal perturbation to normal cell physiology in these cells
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(Figure 4-6D); indeed, separating cells into "low" and "high" infection modes based on
underlying infection bimodality (Figure 4-7D) shows that only highly infected cells harbor
significantly more ISG mRNAs than uninfected controls (Figure 4-7E). These data seemingly
contradict infection-mediated inhibition of IFN signaling under the experimental conditions
investigated, which would predict an inverse correlation between ISG transcripts and infection.
One possible explanation is that negative feedback regulators of IFN signaling, such as
suppressor of cytokine signaling (SOCS) proteins and ubiquitin specific peptidase 18 (USP18),
are less efficiently produced in infected cells [286-288], causing ISG levels to exceed
physiologic levels. This model is consistent with the recent finding that infection induces PKR-
mediated inhibition of host translation [289]. It will be informative to study how such
correlations differ in primary hepatocytes with intact innate immune signaling, and how they
vary across types of IFN, concentrations, and dosing schedules.
In summary, we have demonstrated that multiplexed imaging of vRNA and host transcripts at the
single-cell level can yield unprecedented insights into host-virus interactions. The
generalizability of smFISH to imaging arbitrary mRNAs will enable researchers to determine the
gene expression-infection interrelationship in numerous experimental settings.
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Figure 4-6. Multiplexed quantification of viral positive strands and host mRNA
transcripts in individual cells for dissecting host-virus interactions. (A) Schematic of
concept. A relationship between infection and host gene expression at the single-cell
level (Top) can be identified using multiplexed smFISH to yield a single-cell joint
distribution for these two parameters (Bottom Left); statistics can be performed to
evaluate the association between these parameters, leading to a conclusion that can assist
in addressing hypotheses about host-virus interactions (Bottom Right). (B) Schematic
describing experiment to ascertain relationship between hepatitis C virus (HCV) infection
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and interferon-stimulated gene (ISG) expression by dosing with the Type I interferon
(IFN), IFN-p. Infected (48 hpi) or uninfected cells are dosed with 10 U/mL IFN-P for 12
hours before performing multiplexed smFISH for HCV positive strands and either
EIF2AK2 or ISG15. (C) Typical multiplexed images showing the same field of view 12
hours post dosing of IFN-p in terms of HCV positive strand (Top, scale bar ~ 17.0 Im)
and ISG15 mRNA (Bottom, scale bar ~ 17.0 gm). (D) Joint distributions for
EIF2AK2/HCV (Left) and ISG]5/HCV (Right) visualized as scatter plots. In each plot,
the results of the uninfected experiment are presented on the left (HCV-) where each
point represents the number of ISG mRNA transcripts of individual cells, and on the right
are the results of the pre-infected experiment (HCV+) where each point represents both
the number of HCV positive strands and the number of ISG mRNA transcripts;
progressively more infected cells are rightwards on each plot (green gradient). Gray
points are results pre-IFN treatment (dashed mean and best-fit lines), and red points are
results post-IFN treatment (solid mean and best-fit line). For uninfected cells, increase
post-IFN was statistically significant for EIF2AK2 (****p < 0.0001) and for ISG15
(****p < 0.0001) using two-tailed t test. For infected cells before IFN treatment, there
was no positive correlation between ISG mRNA expression and HCV positive strands for
both EIF2AK2 (p > 0.05) and ISG15 (p > 0.05) as determined by F test on linear
regression parameters. For infected cells after IFN treatment, there was a strong positive
correlation between ISG mRNA expression and HCV positive strands for both EIF2AK2
(****p < 0.0001) and ISG15 (****p < 0.0001) as determined by F test on linear
regression parameters.
4.2.5. Conclusion
In summary, smFISH permits quantitative visualization of individual genomic strands of HCV,
revealing significant virus and host heterogeneity in the process of infection with implications
for viral pathogenesis. The study of this heterogeneity will be particularly illuminating in the
setting of primary cultures and patient tissue samples. We hypothesize that other RNA viruses
are also amenable to smFISH, and given the ideal features of smFISH that encourage adoption,
use of this technique could significantly enhance the study of RNA viruses more generally.
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4.2.6. Personal contributions to this work
The author of this thesis lead a group of researchers in planning, performing, and interpreting
experiments.
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Figure 4-7. Association between viral infection and interferon-stimulated gene (ISG)
expression. (A) Typical smFISH images of EIF2AK2 (Left, Z-stack projection, scale bar
~ 9.5 pm) and ISG15 (Right, Z-stack projection, scale bar ~ 9.5 gm) post IFN-p-
treatment (100 U/mL, 48 hours). (B) Number of ISG mRNA transcripts in individual
cells pre-IFN (gray) or at various times post-IFN-p treatment (10 U/mL) (red) for
EIF2AK2 (Left) and ISG15 (Right). Means are shown as dashed or solid lines for pre- and
post-IFN treatment, respectively. Difference between pre-IFN and 6 hours post-IFN are
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statistically significant for both EIF2AK2 (****p < 0.000 1) and ISG15 (****p < 0.0001).
All differences between post-treatment IFN time-points are non-significant (n.s.) for both
EIF2AK2 and ISG15 (p > 0.05) as determined by one-way ANOVA with Tukey's post-
test. (C) Number of HCV positive strands in individual cells pre-IFN-p and post-IFN-p
(10 U/mL) for 12 h (means in black). Difference was n.s. by two-tailed t test (p > 0.05).
(D) Single-cell distribution of number of positive strands visualized as frequency
histogram reveals bimodality with (i) poorly infected and (ii) highly infected modes. (E)
Number of ISG transcripts in individual cells for both EIF2AK2 (Left) and ISGi5 (Right)
(means in black). On each plot, the number of transcripts in uninfected cells is shown
(HCV-), and on the right (HCV+), the number of transcripts is presented for each cell
after splitting cells into a poorly and highly infected bin based on the number of positive
strands (using 200 strands as a threshold). The difference in ISG expression between
uninfected cells and poorly infected cells is n.s. for both EIF2AK2 and ISG15 (p > 0.05)
as determined by two-tailed t test. The difference in ISG expression between poorly and
highly infected cells is highly significant for both EIF2AK2 (****p < 0.0001) and ISG15
*p < 0.0001) by two-tailed t test.
4.3 Materials and methods
Cell culture
Huh-7 [46], Huh-7.5 [51], and a clone of Huh-7.5 stably integrating the NS3/4A activity reporter [57] were all
propagated in a DMEM- with L-glutamine (Cellgro)-based medium containing 100 U/mL penicillin, 100 pug/mL
streptomycin (Cellgro), and 10% FBS (GIBCO). Primary human fetal liver cells (HFLCs) were isolated and plated
as described [259]. Cultures were maintained in Hepatocyte Defined Medium (HDM) (BD Biosciences) plus L-
glutamine and antibiotics. Induced pluripotent stem cell (iPSC)-derived hepatocyte-like cells (iHLCs) were derived
and cultured as described [82, 181]. For smFISH experiments, cultures were grown on 12 mm, circular, No. 1 glass
coverslips (VWR) in 24-well plates. For Huh-7.5s, attachment to coverslips was improved by coating with rat tail
collagen I (BD Biosciences) at 50 ptg/mL in water for 1 hour at 37'C and then rinsing prior to seeding. HFLC
attachment was enhanced by first coating with collagen and subsequently with poly-L-lysine hydrobromide (Sigma)
at 100 pg/mL for 45 minutes at room temperature and then rinsing prior to seeding. To put iHLCs on coverslips,
they were treated with accutase (Millipore) for 15-20 minutes until they balled up. Gentle pipetting was performed
to remove the cells, and they were then plated onto Matrigel-coated coverslips.
Hepatitis C virus infection, antiviral treatment, and interferon treatment
Hepatoma and iHLC infections were performed with a Gaussia luciferase-expressing reporter virus based on the
efficient Jcl HCV construct [290]; stocks of this reporter were obtained as described [207]. HFLC infections were
performed either with this Jcl reporter or with an adapted HCV called J6/JFH Clone 2 [291]. Titration on naive
Huh-7.5s was used to determine 50% tissue culture infectious dose (TCID50) of stocks of these strains of HCV. For
infection experiments, we employed three standard models of HCV infection: the Huh-7.5 hepatoma cell line (as
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well as the associated Huh-7 cell line and the clone of Huh-7.5 stably expressing the NS3/4A activity reporter as
described below) [251], primary human fetal hepatocytes [259], and induced pluripotent stem cell-derived
hepatocyte-like cells [181]. Stocks were diluted in the appropriate culture medium to make an inoculum with final
titer typically in the 105-106 TCID50/mL range. Cultures to be infected were incubated in inoculum for varying
durations depending on the experiment. Subsequently, medium was typically changed every 24-48 hours unless
otherwise noted, and cultures were washed with culture medium three times between medium changes. To
demonstrate that smFISH imaging of HCV genomes is replication-dependent, the HCV non-structural protein 5B
(NS5B) polymerase inhibitor 2'-C-methyladenosine (2'CMA), with EC50 = 27 nM [251], was used to supplement
both the inoculum and subsequent fresh medium at a concentration of 80*EC5o (final 0.1% DMSO) and compared to
a DMSO-only control. Human interferon P (IFN-p) (Calbiochem) was used to treat cells as described.
Single-molecule RNA FISH (smFISH)
smFISH on culture samples is performed as described in detail [168]. All protocols are also available online at
http://www.singlemoleculefish.com. Briefly, culture samples on coverslips are fixed in 4% w/v paraformaldehyde
(Electron Microscopy Sciences) in PBS for 10 minutes. After washing with PBS, samples can be maintained in PBS
for at least one week at 4'C. Six hours prior to hybridization with probes, samples are permeabilized by placing in
70% EtOH in water at 4*C. Coverslips are incubated in hybridization buffer containing a probe set targeting the
RNA species of interest (BioSearch Technologies; http://www.singlemoleculefish.com; probe sets were designed
targeting the Gaussia-luciferase-expressing HCV reporter described above), each probe of which is coupled to
desired fluorescent molecule (typically Alexa594 or Cy5). Multiple probe sets coupled to spectrally distinct probe
sets can be hybridized to sample simultaneous for multiplexed imaging. Finally, samples are washed, during which
time fluorescent molecules targeting antigens of interest or immunofluorescence antibodies can be incorporated as
described [168], and subsequently mounted for imaging. In this study, endoplasmic reticulum staining was
performed using the ER-ID Green assay kit (Enzo Life Sciences), and HCV non-structural protein 5A (NS5A)
immunostaining was performed using mouse anti-NS5A (9E 10) and goat anti-mouse Alexa Fluor 594 (Invitrogen).
Microscopy and image analysis
Standard epifluorescence microscopy can ascertain smFISH spots as described [168]. All images were taken with a
Nikon Ti-E inverted fluorescence microscope equipped with a lOOX oil-immersion objective and a Photometrics
Pixis 1024 CCD camera using MetaMorph software (Molecular Devices, Downington, PA). Z-stacks were obtained
as described [168]; typically, 20-30 planes separated by 0.4 ptm was sufficient to comprehensively cover the target
cells. Images presented as slices from the Z-stack or maximum intensity projections as described. Images were
analyzed to extract data we show using custom software written in MATLAB (The MathWorks), which can identify
spots on individual channels, assess co-localization, and quantify spots. Quantification has an upper-bound for each
cell that depends on cell volume (height and cross-section), subcellular distribution of target RNA, quality of
imaging, and signal-to-noise ratio. At later time-points post infection (-48 hours), the number of positive strands as
visualized using an Alexa594 fluorophore probe set typically was deemed too large to be counted computationally
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without significant error in a small portion of the cells. For these cells, an estimate was obtained by integrating the
fluorescence intensity in a sum projection of the Z-stack for the cell and subtracting the local background, and
comparing this quantity with that of countable cells to extrapolate an estimate [170]. In order to obtain spot intensity
distributions, we used custom-written MATLAB software to reduce the stacked images to two-dimensional images
by maximum projection, and fitted the fluorescent spots to a 2D Gaussian as the model for the point spread function.
Single transcript intensity was defined as the integrated intensity of the spot using the two-dimensional Gaussian
mask algorithm.
HCV non-structural protein 3/4A (NS3/4A) activity reporter
As previously described [57], we developed a real-time fluorescence reporter of HCV infection based on monitoring
NS3/4A protease activity. A clone of Huh-7.5 stably expressing the RFP-NLS-IPS was used to determine the
correlation between smFISH imaging of HCV genomes and NS3/4A protease activity.
Strand specific qPCR of HCV RNA
Non-infectious positive strand standards were constructed by digesting a plasmid containing J6/JFH1 "Clone 2"
virus (Walters, et al. 2009) with Sac (NEB) and religating the backbone. After XbaI digestion, this DNA was used
in a T7 transcription reaction to yield a 3516nt RNA standard with intact 5' and 3' ends. For minus strand standard
synthesis, we employed an overlap PCR approach to flip the orientation of the positive strand standard. Generated
RNA stocks of both strands were equilibrated via nanodrop to a calculated concentration of 1010 copies/ul. Standard
curves were generated by serially diluting the RNA standards in the presence of fixed 50ng amounts of total RNA
from uninfected Huh-7.5 cells. For qPCR of unknown samples, RNA was isolated using the RNeasy Plus Mini kit
(Qiagen, Valencia, CA) from infected Huh-7.5 cells. Approx 50ng of total RNA was then used for PolyAdenylation
using E. coli PolyA Polymerase (New England Biolabs, Ipswich, MA) using 1mM ATP, 3U E-PAP and 7.5U
RNAsin Plus RNAse inhibitor (Promega, Madison, WS) in a 5ul total reaction volume, and incubated for 10 minutes
at 370C followed by 20 minutes at 650C to inactivate the enzyme. The resulting RNA underwent reverse
transcription using Superscript III (Life Technologies, Carlsbad, CA) following the manufacturers' instructions and
using the tagged RT primer (5'-...TTTTTTTTTTTTTTTTTTTVN-3') at a final concentration of 2.5uM. Approx
2ng of the resulting cDNA was used per subsequent qPCR reaction using 2x FastStart SYBRGreen qPCR mix
(Roche) following the manufacturer's instructions and using a 2.5uM primer for the tag sequence
(GAATCGAGCACCAGTTACGCATG) and either the positive strand primer (CTGGTCTCTCTGCAGATCATGT)
or the negative strand primer (CTGCGTGAAGACAGTAGTTCCTCA) also at 2.5uM. For convenience in many
experiments, we adapted the miScript RT kit (Qiagen) which employs a polyA-tailing and RT step with the above
RT primer in a single reaction, to produce the necessary input for subsequent qPCR using HCV specific primers and
the tag primer. qPCR was carried out using iQ5 thermal cyclers (BioRad) using the following cycling paramters:
95*C for 10minutes, 40x (95 0C for 15s, 58"C for 15s, 72*C for 20s collecting fluorescence), 95*C for 2 minutes,
55"C for 2 minutes followed by fluorescence measurement for each 0.5'C interval increase to 95"C to generate melt
curves.
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Statistical analysis
Error bars plotted as standard deviation (o) or as standard error of the mean (SEM) as noted. Statistical analysis
performed as described - two-tailed t test, one-way ANOVA with Tukey's post-test, linear regression, and F test for
determining positivity of slope performed using GraphPad Prism 5 (GraphPad Software). Pearson correlation
coefficients obtained using MATLAB (The MathWorks).
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Chapter 5. Perspectives and future directions
Viruses are responsible for substantial global morbidity and mortality, with a significant
percentage of the world suffering from infection by one of hepatitis C virus (HCV), hepatitis B
virus (HBV), and human immunodeficiency virus (HIV). As in disease broadly, improvements in
experimental methodologies directly accelerate translational research; to this end, the goal of this
thesis was to develop technologies for the study of viral infection and to demonstrate their use.
Though this thesis focused specifically on the study of HCV, the techniques, analyses, and
concepts introduced here can likely be extended to other viruses and microbes more generally.
Here, we reflect on our results and discuss future trajectories for these projects.
We first envisioned a system for "personalizing" the study of infection, by obtaining patient-
specific somatic cells; reprogramming them into induced pluripotent stem cells (iPSCs);
differentiating them into an adult tissue (in this case, hepatocytes) that is permissive to a
pathogen of interest (in this case, HCV); and infecting them with the pathogen. Such a paradigm
would enable the investigation of patient-specific natural history of infection and treatment
response, bringing us closer to realizing personalized medicine. While researchers have
developed numerous models of genetic disease employing iPSCs from individuals with genetic
mutations, this approach has not been pursued in the study of infection. Technical barriers have
in general forced researchers to perform studies in a small number of host models, raising the
question of generalizability of findings to the broader population. Research is gradually revealing
how important the host background is; in hepatitis C for example, it has long been known that
only some patients respond to interferon regimens, and genome-wide association studies
(GWAS) have determined that a polymorphism in the interleukin-28b (IL-28b) is predictive of
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this response. However, while these and other genetic factors are known to influence infection
phenomena, we do not mechanistically understand how they underlie such differential responses.
Obtaining such an understanding necessitates an in vitro model of infection that captures host
genetics, and the emergence of iPSC technology enables the sourcing of such models. By
showing in this thesis that iPSC-derived adult tissue can be permissive to a pathogen, we have
demonstrated the feasibility of "personalizing" the study of infection.
This work opens the door to numerous investigations. First, it is now possible to systematically
obtain iPSC lines from numerous patients with backgrounds of interest, and to study infection in
these different contexts. For HCV in particular, iPSC lines can be acquired from individuals with
IL-28b polymorphisms and with known mutations in genes relevant to viral pathogenesis such as
signal transducer and activator 1 (STA Ti) and low-density lipoprotein receptor (LDLR). It will be
particularly exciting to study patients with unique clinical trajectories but for which no known
genetic mutations have yet been ascribed, such as fulminant hepatitis patients. The study of how
infection in these different genetic backgrounds responds to therapy differentially will be
especially valuable, paving the way for "customized treatment" of individual patients. Second,
we are determining whether it is possible to develop personalized animal models of infection.
Though animal models are a mainstay in the development of therapy and in illuminating systems
pathophysiology, animal models of HCV infection have been elusive largely due to the primate
tropism of HCV. Our lab has recently described the development of robust, "humanized" mice
[292], in which a tissue-engineered "organoid" carrying hepatocytes is transplanted
intraperitoneally; these organoids integrate with mouse vasculature, through which they can
serve as ectopic livers. It will be fruitful to determine whether iPSC-derived hepatocytes can be
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cultivated in these organoids and subsequently transplanted into animals, furnishing a
personalized, humanized mouse that could be used to study patient-specific infection in vivo.
Third, the ability to coax iPSCs from the pluripotent stage to hepatocytes makes it possible to
study the onset of HCV-permissiveness throughout this maturation; thus can enable us to both
identify the minimal host factor machinery necessary for infection, and study the development of
the innate immune response to infection which may progress after the fetal hepatocyte stage
[293]. Finally, it will be natural to show that the paradigm of personalized studies of infection
can be applied beyond HCV.
The second project we described sought to address another major hindrance to the HCV field -
the lack of a primary adult hepatocyte in vitro model of infection. Instead, the HCV research
community and indeed scientists studying liver biology in general have relied extensively on
hepatoma cell lines which suffer from defective signaling, gene expression, proliferation, and
polarization. Partly due to its exceptional permissiveness to HCV, the Huh-7.5 hepatoma cell line
has proven invaluable for HCV basic research and for antiviral screening. Despite this progress,
deviations from expected physiology in this model have cultivated great interest in studying
HCV infection in a more physiologic, primary adult hepatocyte model. Though the stable culture
of primary hepatocytes in vitro has been notoriously challenging, our lab has employed tissue
engineering methodologies to develop a micropatterned co-culture (MPCC) of hepatocytes and
supportive stroma that exhibits long-term liver phenotype maintenance [150]. In this thesis, we
demonstrated that MPCCs are permissive to HCV infection, enabling researchers to begin
studying HCV infection in its native host.
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One unexpected finding in this model was that "isolated" primary adult hepatocytes -
hepatocytes in the absence of liver microenvironmental stimuli - acutely resolve HCV infection.
HCV in vivo has a remarkable tendency to chronicity, partly due to its ability to blunt IFN
signaling; however, despite the absence in MPCCs of innate and adaptive immune effectors,
infection was more rapidly cleared in vitro. By comparison with Huh-7.5s which lack effective
intrinsic innate immunity, we hypothesized that IFN signaling in primary hepatocytes may
constrain HCV infection and showed that this was the case using various methods to interrupt the
IFN pathway. So why is IFN signaling able to eliminate infection only in these "isolated"
primary adult hepatocytes but not in vivo? We hypothesized that signals in the liver
microenvironment may "tolerize" hepatocytes to infection by dampening IFN signaling. It has
long been appreciated that the liver is a remarkably tolerant environment in which innate and
adaptive immune effector cells are exposed to anti-inflammatory agents that mitigate their
immune functions. However, our hypothesis was that the hepatocytes themselves, which are the
primary site of infection, are also exposed to cues that tolerize their IFN signaling. To this end,
we performed a screen of candidate anti-inflammatory compounds in MPCCs which identified
several hits that enhance infection; interleukin (IL)-6 was the most potent, able to enhance
infection 10-30 fold. We confirmed mechanistically that IL-6 blunts the IFN response to
infection, which likely explains its capacity to boost infection so dramatically. IL-6 is normally
secreted by the liver-resident macrophages known as Kupffer cells as a result of their continuous
exposure to lipopolysaccharide (LPS) introduced through the intestinal circulation. It is believed
that this influx of LPS and other microbial antigens would require anti-inflammatory
compensation to prevent the liver from being constantly inflamed. In line with this, we suggest a
model in which LPS-provoked Kupffer cells produce IL-6 that encourages hepatocytes to
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become immunologically inert to avoid inflammation; this quiescence is in turn exploited by
HCV, malaria, and potentially other pathogens, which can establish themselves in a host with
lessened surveillance. Proper elucidation and generalization of this concept will benefit from the
"bottom-up" development of more complex MPCC models incorporating nonparenchymal cell
types such as Kupffer cells to determine how they modulate infection; it is likely that numerous
liver cell types modulate infection in various ways, and we have indeed shown that human liver
fibroblasts, liver sinusoidal endothelial cells (LSECs), mesenchymal stem cells (MSCs), and an
unrefined collection of rat liver nonparenchymal cells (NPCs) all enhance HCV infection.
Finally, it will be possible to verify these findings in vivo using small animal models of
hepatotropic infection, which our lab and others are developing; initial steps towards this could
involve encapsulation of primary hepatocytes in organoids and infection post implantation into
mice. Validation of this concept in vivo would raise the exciting possibility of using inhibition of
IL-6 signaling for hepatotropic pathogens broadly.
The availability of a primary hepatocyte model will be particularly exciting for research where
Huh-7.5s deviate most significantly from normal physiology. Aside from innate immune
signaling, hepatocyte polarity is another such area, with Huh-7.5s being non-polarized. Unlike
simple epithelia, natural hepatocytes demonstrate complex polarization consisting of irregular
apical (bile canalicular) and basolateral (space of Disse) domains separated by tight junctions.
This is relevant to HCV infection. The entry receptors for HCV - CD81, scavenger receptor BI
(SR-BI), and the tight junction proteins claudin 1 (CLDN) and occludin (OCLN) - have distinct
localization profiles on hepatocyte membranes. CD81 and SRBI are primarily basolateral,
whereas CLDN and OCLN are present in the tight junctions at the periphery of the basolateral
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domain. As such, HCV entry is shaped by receptor interactions that are very different on
polarized and non-polarized cells. Further, polarization is intimately correlated with the means of
viral spread. Viruses are thought to have two primary means of spreading from infected to
uninfected cells: "cell-free" transmission whereby virions secreted by an infected cell eventually
infect uninfected cells, and "cell-cell" transmission through which infected cells can somehow
shuttle virions to uninfected cells. It is hypothesized that HCV may exhibit cell-cell spread as
well, with virions being secreted apically into bile canaliculi, through which they can rapidly
enter nearby cells while evading humoral immunity. Polarized primary hepatocytes will be
necessary to test this hypothesis. Using our real-time reporter of infection [192] we have
observed "foci" of infection in MPCCs that start from an initial infectious event (Figure 3-11);
the use of depolarizing agents or micromechanical tools [145] to physically manipulate cells over
small length scales will help determine whether this is truly cell-cell spread as opposed to cell-
free spread with highly local virion diffusion.
A related question to the study of polarization is how cell-cell interactions more generally shape
viral infection. As discussed, homotypic hepatocyte-hepatocyte contact may accelerate viral
spread, but there are far more intercellular signals present, including soluble cues such as IFN
signaling; hepatocyte-fibroblast interactions that encourage local differences between
hepatocytes on the islands (we have shown that peripheral hepatocytes on patterned islands are
indeed more susceptible to viral entry); gap junctional components that may spread inflammatory
signals [294]; cadherins that activate IL-6 signaling [295]; and so on. As the behavior of
infection is likely influenced by these factors, the result of an infection experiment in MPCCs
integrates the complex network of cell-cell interactions present in the decided architecture [246].
109
Fortunately, hepatocytes in MPCCs are intentionally patterned into a desired architecture.
Though the current scheme - islands of a fixed diameter patterned into an array - was
empirically determined to maximize albumin out per cell, it is still possible to produce functional
cultures from a wide array of hepatocyte architectures. It is thus possible to: modulate
architecture; ascertain the resulting infection system using as many sources of information as
possible (viral luciferase reporter, smFISH, reporters of signaling pathway activity, etc.); build
mathematical models predictive of the infection system given an input architecture and the
associated cell-cell interaction network; and use the insights revealed by the mathematical model
to make mechanistic hypotheses implicating particular cell-cell interactions in infection.
The last project was motivated by the scarcity of quantitative, single-cell assays of viral
infection. Aside from having limited specificity and sensitivity that preclude investigations in
low signal-to-noise host systems, typical assays do not provide single-cell data; further, they
generally provide limited information, such as binary assessments of infection. Cellular in situ
imaging has the potential to overcome these limitations, furnishing a high-content source of
information that is drastically enhancing screening as well as basic science. To this end, we
developed an imaging assay for visualizing individual viral genomes that relies on single-
molecule RNA fluorescence in situ hybridization (smFISH) [168]; we showed that smFISH can
be applied in numerous manifestations to extract various quantitative descriptors of infection,
including the single-cell heterogeneity of infection. Like the genomics revolution in molecular
biology that resulted from access to rich data, we envision that our understanding of viral
infection will be fundamentally improved by assays that simultaneously illuminate features of
both virus and host. Single-cell assays are particularly rewarding. For example, one major
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question has been whether interferon-stimulated genes (ISGs) elicited by infection are
upregulated in infected cells or their neighbors; it is believed that HCV diminishes IFN
signaling, in which case infected cells may not be the source of ISGs. Bulk assays of RNA can
only detect whole-tissue changes, with no predictions for the single-cell level. We showed using
smFISH that single-cell infection is correlated with ISG elevation in response to type I interferon
(IFN) stimulation, suggesting that ISG upregulation is not exclusive to uninfected cells. While
smFISH can thus be qualitatively powerful, the resulting rich data can also enable researchers to
be quantitative. For example, several research groups perform theoretical and computational
modeling of the viral life cycle, but the lack of rich data has stymied the fitting of these model
parameters, often relegating these models to being solely descriptive; the access to quantitative
data by assays such as smFISH will empower these models to make accurate predictions,
ultimately enabling hypothesis testing and true inference about infection. To this end, smFISH
could be used to understand viral replication by studying the relative dynamics of HCV positive
and negative strand proliferation. Another promising area for use of smFISH is in the
classification of antiviral mechanism. There are at least two applications in this vein. One
application is the determination of mechanism of an identified antiviral hit. There are no
systematic ways of determining antiviral mechanism, and assays that can reveal numerous
features of infection such as smFISH can act as powerful classifiers of antiviral function. A
second application is in empowering small-molecule screens to find compounds with unique
antiviral functions. Most known antiviral compounds typically fall into a small number of
functional categories (e.g. polymerase inhibitors), and because it is believed that the genetic
barrier to resistance emergence is maximized using functionally orthogonal antivirals, it is of
great interest to diversify our antiviral portfolios. Assays such as smFISH that yield unique
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descriptors of infection will help execute high-throughput screens for compounds that perform
novel functions. Another valuable study will involve employing smFISH for detecting HCV in
tissue sections. Assays for HCV infection in liver tissue have generally proven ineffective,
possibly due to low viral signals combined with the high intrinsic autofluorescent background in
liver sections; as smFISH has been demonstrated in tissue sections for mRNA imaging, it is
likely to be fruitful in the study of HCV-infected liver samples as well. Finally, it will be of
immediate interest to utilize smFISH to study other viruses as well, to both benefit the
investigation of these viruses and evaluate RNA virus comparative biology.
One important HCV in vitro model development challenge remains. Despite significant research,
for reasons that are unclear, only strains of HCV based on one genotype 2a isolate from a
fulminant hepatitis patient - Japanese Fulminant Hepatitis 1 (JFH- 1) - are robustly infectious in
vitro. As such, it is impossible to study the differential pathogenesis and treatment responses of
various HCV strains; this is particularly concerning because the strain predominant to the
Western World, genotype la, is far more resistant to IFN therapy. While most researchers
tackling this problem focus on determining the unique features of JFH-1 that permit replication
in vitro and imbuing other viral strains with these features [32], we suggest an alternate approach
- as all these strains are obviously infectious in vivo, it may be worthwhile asking which
important in vivo features are absent in our models and adding these features to our in vitro
models. One hypothesis is that the standard host cells, Huh-7.5s, have abnormalities inconsistent
with non-JFH- 1 strain viability. However, preliminary experiments have demonstrated that these
strains infect abortively in MPCCs as well. Interestingly, inhibition of IFN signaling using the
methods described above, including IL-6, boost infection albeit transiently. This is consistent
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with IFN signaling presenting a barrier to infection, but that innate immunity does not fully
explain their lack of growth in primary hepatocytes. It will be worthwhile adding other liver
nonparenchymal cell types with or without spatial patterning, recapitulating other known soluble
signals present in the liver, trying experiments in 3D cultures, adding flow or mechanical shear
using microfluidics, and so on. Studying the nature of the abortive infection of non-JFH-1
strains, for example using smFISH or reporters of pathway activity, will help yield insights
regarding what stages of infection these strains fail to complete. This work is an open frontier for
future research in HCV model development.
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